βIV-spectrin-polypeptides and nucleic acids encoding same

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates to proteins, polypeptides, or fragments thereof, which interact with autoantigens of autoimmune diseases, such as type I diabetes. More particularly the invention relates to polypeptides, or fragments thereof, which interact with human ICA512 and phogrin. The invention also relates to nucleic acid sequences which encode these polypeptide or polypeptide fragments. The invention also relates to methods for identifying and treating individuals who suffer from or are susceptible to diabetes, screening for autoimmune diseases such as type I diabetes, and modulating hormone and neuropeptide secretion using proteins or protein fragments which interact with autoantigens of autoimmune diseases.

2. Description of the Related Art

Insulin dependent diabetes mellitus (also known as IDDM or type I diabetes) primarily afflicts young people. Although insulin is available for treatment, the several-fold increased morbidity and mortality associated with this disease urge the development of early diagnostic and preventive methods. The destruction of pancreatic β-cells, which precedes the clinical onset of IDDM, is mediated by autoimmune mechanisms. Among the most thoroughly studied autoimmune abnormalities associated with the disease is the high increase of circulating β-cell-specific autoantibodies at the time of diagnosis.

A major goal of diabetes research has been to develop immune interventions that block or inhibit the destruction of β-cells and development of IDDM. For example, U.S. Pat. No. 5,512,447, the disclosure of which is incorporated herein by reference, describes assays for the detection of diabetes and prediabetic status by exposing patient serum samples to purified ligand capable of binding autoantibodies specific for a 64 kD autoantigen present in pancreatic β-cells. One of the most intriguing observations resulting from studying the cell biology of β-cell autoantigens is that all major targets of IDDM autoantibodies identified thus far are directly connected with the secretory apparatus of β-cells (Solimena, Diabetes, Metab. Rev. 14:227-240 (1994)).

A large body of evidence indicates that protein and lipid phosphorylation participates in the trafficking of secretory granules (SGs), synaptic vesicles (SVs), and synaptic-like microvesicles (SLMVs) of neuroendocrine cells, including pancreatic β-cells. Several membrane and cytosolic phosphoproteins involved in priming, docking and fusion of regulated secretory vesicles (Ferro-Novick, S. et al., Nature 370:191-193 (1994); Martin, T. F., Curr. Opin. Neurobiol. 4:626-632 (1994); Calakos, N. et al., Physiol. Rev. 76:1-29 (1996)) have been shown to be substrates for serine/threonine phosphorylation (Greengard, P. et al., Science 259:780-785 (1993); Ashcroft, F. M. et al., J. Cell Biochem. 55 Supp:54-65 (1994)). However, less evidence is available implicating tyrosine phosphorylation in these processes. The following evidence suggests that tyrosine phosphorylation may play a role in regulated secretion.

The protein tyrosine kinase (PTK) inhibitors genistein and herbimycin A both stimulate insulin secretion in neonatal islets (Sorenson, R. L. et al., Endocrinol. 134:1975-1978 (1994)), and genistein has been shown to affect the ATP-dependent priming of SGs in semi-intact PC12 cells (Hay, J. C. et al., J. Cell Biol. 119:139-151 (1992)). In GH3 cells, both PTK and protein tyrosine phosphatase (PTP) inhibitors have been shown to impair the biogenesis of SGs from the trans-Golgi network (Austin, C. D. et al., J. Cell Biol. 135:1471-1483 (1996)) as well as modulate the activity of L-type Ca

2+

channels (Cataldi, M. et al., J. Biol. Chem. 271:9441-9446 (1996)) which are known to be coupled to neurosecretion.

Synaptophysin and synaptogyrin, two intrinsic membrane proteins of SVs, have both been shown to be tyrosine phosphorylated (Pang, D. T. et al., Proc. Natl. Acad. Sci. U.S.A. 85:762-766 (1988); Stenius, K., et al., J. Cell Biol. 131:1801-1809 (1995)), but the physiological relevance has not yet been determined. Furthermore, PTK pp60

c-src

has been shown to be peripherally associated with regulated secretory vesicles, including SGs of chromaffin cells (Parsons, S. J. et al., Biochem. Biophys. Res. Comm. 134:736-742 (1986); Grandori, C. et al., J. Cell Biol. 107:2125-2135 (1988)).

Annexins (soluble Ca

2+

and phospholipid-binding proteins) have been implicated in exocytosis in different cell types, including endocrine cells (Burgoyne, R. D. et al., J. Anat. 183:309-314 (1993)). Annexin II, in particular, has been shown to bind chromaffin SGs and to reconstitute secretion from permeabilized chromaffin cells of the adrenal medulla (Sarafian, T. et al., C.J. Cell Biol. 114:1135-1147 (1991)), and has been shown to be tyrosine phosphorylated by 60

c-src

(Hubaishy, I. et al., Biochemistry 34:14527-14534 (1995)). pp60

c-src

has also been shown to phosphorylate botulinum A and E (Ferrer-Montiel, A. V. et al., J. Biol. Chem. 271:18322-18325 (1996)), two clostridium neurotoxins which cause the block of neurosecretion and paralysis by cleaving the synaptobrevin binding protein SNAP-25 at neuromuscular junctions (Tonello, F. et al., Adv. Exp. Med. Biol. 389:251-260 (1996)). Since tyrosine phosphorylation enhances the protease activity of both botulinum A and E, it is possible that tyrosine phosphorylation and regulated secretion are coupled in certain cells.

Islet cell autoantigen 512 (ICA512, also known as IA-2 and PTP35), is an intrinsic membrane protein of SGs which is expressed in virtually all neuroendocrine cells including peptide-secreting endocrine cells, neurons of the autonomic nervous system, and neurons of the hypothalamus and the amygdala in the brain (Solimena, M. et al., EMBO J. 15:2102-2114 (1996)). Human ICA512 has been identified as an autoantigen of IDDM (Rabin, D. U. et al., Diabetes 41:183-186 (1992); Rabin, D. U. et al., J. Immunol. 152:3183-3188 (1994); Lan, M. S. et al., DNA Cell Biol. 13:505-514 (1994)), and has been postulated to play a role in regulated peptidergic secretion from neuroendocrine cells, including insulin-secreting cells of the pancreatic islets. The open reading frame of human ICA512 encodes a protein of 979 amino acids (FIG.

1

). The sequence includes a signal peptide (residues 1-34) and two putative N-glycosylation sites (residues 506 and 524) in the extracellular domain (residues 1-575, henceforth defined as ectodomain), a single transmembrane domain (residues 576-600), and a cytoplasmic domain (residues 601-979) which includes a region displaying homology to protein tyrosine phosphatases (PTPs) (residues 696-979). Like several other enzymatically active receptor protein tyrosine phosphatases (RPTPs) (Streuli, M. et al., EMBO J. 11:897-907 (1992); Serra-Pages, C. et al., J. Biol. Chem. 269:23632-23641 (1994); Brady-Kalnay, S. M. et al., J. Biol. Chem. 269:28472-28477 (1994); Pulido, R. et al, Proc. Natl. Acad. Sci. U.S.A. 92:11686-11690 (1995)), ICA512 is processed within its ectodomain (Solimena, M. et al., EMBO J. 15:2102-2014 (1996); Hermel et al., Eur. J. Neurosci. 11:20690 (1999)). Cleavage of ICA512 (arrow in

FIG. 1

) generates a 65 kD transmembrane fragment (residues 449-979) which remains associated with SG membranes, and a putative N-terminal fragment (residues 35-448).

The cytoplasmic domain of ICA512 is homologous with PTPs and suggests that ICA512 participates in signal transduction pathways involving tyrosine phosphorylation. Several features, however, distinguish ICA512 from conventional RPTPs.

First, the ectodomain of human ICA512 does not contain any of the motifs found in most RPTPs, including Ig domains, type III fibronectin repeats, MAM (meprin, A5, PTPμ) domains, or carbonic anhydrase-like motifs, all of which are thought to mediate cell—cell or cell-matrix contact (Brady-Kalnay, S. M. et al., Curr. Opin. Cell Biol. 7:650-657 (1995); Streuli, M. Curr. Opin. Cell Bio. 8:182-188 (1996)). (The RGD motif of the type III fibronectin repeat, however, is present once in the ectodomains of rat and mouse ICA512 (Passini, N. et al., Proc. Natl. Acad. Sci. U.S.A. 92:9412-9416 (1995); Lu, J. et al., Biochem. Biophys. Res. Comm. 204:930-936)).

Second, ICA512 joins phogrin and striate enriched phosphatase (STEP) isoforms as a member of the RPTP family which resides in an intracellular compartment (Rydelk, F. L. et al. Soc. Neurosci. 22:1005 (400.5) (1996); Bult A., et al., J. Neuroscience 16:7821-7831 (1996)). In contrast, the majority of other receptor protein tyrosine phosphatases are believed to be constitutively expressed at the plasma membrane. Phogrin (also known as IA-2β or ICAAR), in particular, is a mammalian protein with significant structural and most likely functional homology to ICA512 (Wasmeier, C. et al., J. Biol. Chem. 271:18161-18170 (1996)). Phogrin is also associated with secretory granules of neuroendocrine cells, including β-cells, and is an autoantigen of IDDM (Pietropaolo, M. et al., Diabetes Care 20:208-214 (1997); Hatfield, E. C., Diabetologia 40:1327-1333 (1997)).

Third, recombinant ICA512 does not display PTP activity when tested with common PTP substrates (Rabin, D. U. et al., Diabetes 41:183-186 (1992); Lan, M. S. et al., DNA Cell Biol. 13:505-514 (1994); Lu, J. et al., Biochem. Biophys. Res. Com. 204:930-936 (1994)). The lack of catalytic activity of ICA512 results from two amino acid substitutions within its PTP homology domain: an aspartic acid (D) instead of an alanine (A) at position 911 within the so-called PTP “signature motif”, and an alanine instead of an aspartic acid at position 877. However, an ICA512 mutant in which alanine 877 and aspartic acid 911 have been replaced with aspartic acid and alanine, respectively, displays PTP activity similar to conventional PTPs (Magistrelli, G. et al., Biochem. Biophys. Res. Comm. 227:581-588 (1996)). In addition, replacement of aspartic acid with alanine within the PTP signature motif of phogrin is sufficient to confer PTP activity (Rydelk, F. L. et al. Soc. Neurosci. 22:1005 (400.5) (1996)).

There is evidence that other members of the RPTP family interact with proteins of the spectrin family. CD45, a receptor involved in T- and B-cells proliferation, has been shown to bind βII-spectrin (also known as β-fodrin) via its C-terminus PTP domain (Iida et al., J. Biol. Chem. 269:28576-28583 (1994)). Strikingly, this PTP domain in CD45, like that in ICA512, contains an aspartic acid rather than an alanine within its PTP signature motif and appears to be enzymatically inactive. A protein termed TRIO, which contains multiple spectrin repeats, has been recently found to interact with the regulatory, enzymatically inactive, PTP domain of RPTP LAR (Debant, A. et al., Proc. Natl. Acad. Sci. U.S.A. 93:5466-5471 (1996)). Taken together, this data suggests that modified, non-catalytic PTP domains may mediate the interaction of RPTPs with the actin cytoskeleton via an interaction with different members of the spectrin family.

There is also evidence that spectrins can be the targets of autoimmunity in human diseases. For instance αII-spectrin (also known as α-fodrin) has been recently found to be a major autoantigen in Sjorgren syndrome (Haneji, N. et al., Science 276:604-607 (1997); Yanagi et al., Eur. J. Immunol. 28:3336 (1998)), a disorder resulting from the autoimmune infiltration of the salivary gland. Recently, both cellular and humoral autoimmunity directed against αII-spectrin has been detected in the non-obese diabetic (NOD) mouse (Yanagi et al., Eur. J. Immunol. 28:3336-3345 (1998)), a mouse strain that spontaneously develops an autoimmune sialadenitis resembling human Sjogren syndrome as well as an autoimmune diabetes resembling human type I diabetes. These data raise the question of whether autoimmunity directed against αII-spectrin can develop in type I diabetic patients in the absence of Sjogren syndrome. Relevant to this question is whether αII-spectrin is expressed in pancreatic β-cells. To the inventor's knowledge, no members of the spectrin family, including αII-spectrin, has been reported to be expressed in pancreatic β-cells.

Heretofore, studies on vesicular trafficking in neuroendocrine cells and signal transduction via tyrosine phosphorylation have proceeded without significant overlap. Recently, however, it has been postulated that a close relationship may exist between the cell biology of regulated secretion and the organization of the cortical cytomatrix, a preferential target for tyrosine phosphorylation. ICA512 and phogrin could each play a role in regulating peptide hormone secretion and/or survival and differentiation of neuroendocrine cells. However, the precise role of these autoantigens remains elusive, as the proteins appear to lack PTP activity. Therefore, there is a need in the diabetes treatment art for the identification, isolation, and characterization of protein molecules, or fragments thereof, that associate with autoantigens of type I diabetes, such as human ICA512 and phogrin, in order to assist in the determination of the precise role of these autoantigens in peptide hormone secretion. In addition, such proteins, or fragments thereof, could be the targets of autoimmunity in human diseases related to peptide hormone secretion, including IDDM, and hence would be useful as a tool in attenuating or screening for such diseases. The present invention is believed to be an answer to that need.

SUMMARY OF THE INVENTION

In one aspect, the present invention relates to an isolated polypeptide (termed βIV-spectrin), or a fragment thereof, the isolated polypeptide, or fragment thereof, having an amino acid sequence shown in SEQ ID NO:2 (FIG.

3

), or a fragment thereof.

In another aspect, the present invention relates to an isolated nucleic acid which codes for a polypeptide, or fragment thereof, wherein the polypeptide or fragment thereof has the amino acid sequence shown in SEQ ID NO:2 (FIG.

3

), or a fragment thereof.

In another aspect, the present invention relates to a method for identifying the presence of type I diabetes in a patient, comprising the steps of (a) contacting body fluid from the patient with an isolated polypeptide, or fragment thereof, which interacts with an autoantibody of type I diabetes to form a complex, the isolated polypeptide or fragment thereof comprising the amino acid sequence shown in SEQ ID NO:2 (FIG.

3

), or a fragment thereof; and (b) detecting the presence or absence of the complex.

In yet another aspect, the present invention relates to a method of modulating neuropeptide or hormone release in a patient, comprising the step of administering to a patient a therapeutic amount of a compound which affects the interaction of an autoantigen of type I diabetes and a polypeptide which interacts with the autoantigen of type I diabetes, the polypeptide having the an amino acid shown in SEQ ID NO:2 (FIG.

3

), or a fragment thereof. Preferably, the compound binds to the product of a gene that encodes a polypeptide having an amino acid sequence comprising at least one sequence of Glu-Arg-Gln-Glu-Ser (SEQ ID NO:3).

In yet another aspect, the present invention relates to a pharmaceutical composition comprising a therapeutic amount of a compound which affects the interaction of an autoantigen of type I diabetes and a polypeptide which interacts with the autoantigen of type I diabetes in a pharmaceutically acceptable carrier, the polypeptide having the amino acid sequence shown in SEQ ID NO:2 (

FIG. 3

) or a fragment thereof, the pharmaceutical composition effective to modulate neuropeptide or hormone release in a patient. Preferably, the compound binds to the product of a gene that encodes a polypeptide having an amino acid sequence comprising at least one sequence of Glu-Arg-Gln-Glu-Ser (SEQ ID NO:3).

These and other aspects will become apparent upon reading the following detailed description of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

The file of this patent contains at least one drawing executed in color. Copies of this patent with color drawing(s) will be provided by the Patent and Trademark Office upon request and payment of the necessary fee.

The invention will be more fully understood from the following detailed description taken in conjunction with the accompanying drawings in which:

FIG. 1

is a schematic diagram of the domain structure of human ICA512;

FIGS. 2A-B

are photographs showing the results of a two-hybrid screening in yeast for ICA512 and phogrin binding proteins and C-D are western blot analyses for the expression of ICA512 cytoplasmic domain, phogrin cytoplasmic domain, and a polypeptide encoded by the IV-spectrin gene (hereafter termed B8);

FIG. 3

is a photograph of an immunoprecipitation and western blot analysis of the fragment of IV-spectrin B8 interacting with ICA512 protein;

FIG. 4

is a schematic diagram of the partial domain structure of human IV-spectrin polypeptide;

FIG. 5

shows the partial cDNA (SEQ ID NO:1) and deduced polypeptide (SEQ ID NO:2) sequences for human IV-spectrin;

FIG. 6

is a photograph showing fluorescent in situ hybridization for βIV-spectrin;

FIG. 7

are autoradiograms showing the results of Northern blot analysis using portions of the βIV-spectrin cDNAs as probes;

FIG. 8

are autoradiograms of Northern and Western blots for βIV-spectrin in human islets;

FIG. 9

is a photograph showing the results of stained confocal microscopy on sections of rat pancreas probed with an antibody directed against βIV-spectrin; and

FIG. 10

is a photograph showing expression of αII spectrin in pancreatic islet cells.

DETAILED DESCRIPTION OF THE INVENTION

It now has been surprisingly found, in accordance with the present invention, that an answer is provided to the problem of identifying, isolating, and characterizing a protein or protein fragment that associates with autoantigens of type I diabetes, particularly ICA512 and phogrin. The present inventors have solved this problem by isolating, identifying, and partially cloning a novel human protein termed βIV spectrin, a new member of the spectrin family, which selectively associates with the cytoplasmic domain of human ICA512 (ICA512

cyt

) and phogrin. As an interactor of ICA512 and phogrin, βIV-spectrin is a potential target of autoimmune diseases, such as type I diabetes, and is useful in screening sera and body fluids from individuals affected by type I diabetes or at risk of developing this disease. In addition, βIV-spectrin is a potential target for pharmacological intervention in disorders such as diabetes which result from impaired hormone secretion.

Since βIV-spectrin is a new member of the spectrin family as described in detail hereinbelow, the present inventor postulates that other members of the spectrin family (i.e., those proteins with spectrin or spectrin-like repeats in their amino acid sequences), such as alpha and beta isoforms of erythroid spectrin and non-erythroid spectrin (β-fodrin), may also associate with autoantigens of type I diabetes and thus represents additional targets of autoimmunity in such disease. Accordingly, the methods and compositions of the present invention are not limited to βIV-spectrin, but includes all members of the spectrin family that associate with autoantigens of type I diabetes.

As used herein, the term “interacts” is defined as any mutual or reciprocal interaction between molecules, particularly the binding between two or more molecules.

As defined herein, the term “autoantigen” refers to a molecule created by an organism, such as a human, for which there is an immune response by that organism, for example, generation of ICA512 or phogrin.

As defined herein, the phrase “spectrin repeat” or “spectrin-like repeat” refers to one or more sequences of amino acids that are characteristic of those proteins which are members of the spectrin family.

The original cDNA clone encoding a portion of the βIV spectrin gene was isolated following a screening for human brain proteins interacting with the cytoplasmic domain of ICA512 by two hybrid assay in yeast. The two-hybrid system in

S. cerevisiae

is an assay in which protein-protein interactions are identified in vitro through the reconstitution of the activity of a transcriptional activator (Fields, S. et al., Nature 340:245-246 (1989)). In general, this system is well suited for the identification of interactions that occur in the cytosol or the nucleus. The conventional two-hybrid system is based on the modular structure of eukaryotic transcription activators, many of which contain two distinct domains: one which binds DNA and other which activates transcription. To promote transcription, the DNA-binding and activation domains must be adjacent, but not covalently attached. In this method, the cDNA encoding for a DNA-binding domain is fused to the cDNA of a protein (“bait”) for which interactors are to be found, whereas the cDNA for a transcription activation domain is fused to proteins (“preys”) encoded by a cDNA library. The bait and prey fusion genes reside on independent plasmids which are co-transformed into a yeast strain whose growth in media lacking an essential amino acid (such as histidine) depends on the expression of the corresponding biosynthetic enzyme. This occurs only when the association of the two fusion proteins brings the DNA-binding and transcription activation domains into close proximity. In a similar fashion, the interaction of the bait and prey induces the expression of β-galactosidase encoded by the LacZ gene.

For the present invention, the yeast two-hybrid screening was executed according to the protocol of Vojtek (Vojtek et al., 1993). Briefly, the cDNAs encoding for the cytoplasmic domains of the wild-type human ICA512 (a.a.600-979, ICA512-cyt), human phogrin (a.a. 640-1015, phogrin-cyt) and the ICA512 A877D911/D877A911 (ICA512-cyt AD/DA) mutant were amplified by polymerase chain reaction (PCR) and independently subcloned into the pLexA vector, creating fusion proteins with the LexA binding domain. The ICA512 AD/DA mutant was constructed using site directed mutagenesis of human ICA512 in pRC/RSV (Invitrogen, Carlsbad, Calif.) with the QuickChange mutagenesis kit (Stratagene, La Jolla, Calif.) according to the manufacturer's instructions (A877/D877, 5′ primer: CCTCAGCTGGCCGGACGAGGGCACACCGG (SEQ ID NO:4), 3′ primer: CCGGTGTGCCCTCGTCCGGCCAGCTGAGG (SEQ ID NO:5); D911′A911, 5′ primer: CGTGCACTGCTCGGCCGGTGCGGGGAG (SEQ ID NO:6); 3′ primer: CTCCCCGCACCGGCCGAGCAGTGCAC (SEQ ID NO:7). Insertion of point mutations was verified by restriction analysis and automated sequencing. The cytoplasmic domain of human phogrin was amplified by PCR from a human adult brain cDNA library in pACT2 (Clontech, Palo Alto, Calif.) and analyzed by automated sequencing. pLexA-ICA512-cyt, pLexA-ICA512-cyt AD/DA and pLexA-phogrin cyt were independently transformed into the yeast strain L40 (partial genotype MATa trp1 leu2 his3 LYS2::lexA-HIS3 URA3::lexA-lacZ) and AMR70. Expression of the LexA-fusion proteins (baits) was verified by western blotting using a pLexA-antibody (Invitrogen, Carlsbad, Calif.). L40 cells expressing pLexA-ICA512cyt were co-transformed with 500 μg human adult brain MatchMaker cDNA library in PACT2 (Clontech). Double transformants were selected and screened for His+ and LacZ+ phenotype, demonstrating the presence of a functional ligand for ICA512cyt. Screening of 1×107 double transformants yielded about 800 His+ colonies, of which about 540 were LacZ+. A subset of these clones was screened a second time by a mating assay. Briefly, after the purging of the bait plasmid (pLexA-ICA512cyt), the L40 His+ LacZ+ cells carrying the prey plasmids were mated with AMR70 cells transformed either with LexA-ICA512cyt, LexA-ICA512cyt, AD/DA or LexA-phogrin cyt. Mating with LexA-lamin and LexA-mss4, two mammalian proteins unrelated to ICA512 and phogrin, allowed segregation of false positive clones from putative ICA512 interactors. One of the clones that fulfilled the requirements for specificity of the mating assay was sequenced completely on both strands. This clone, termed B8, contained an insert of 2,420 base pair located at the 3′ end of a novel gene with sequence similarity to members of the spectrin family.

Panel A of

FIG. 2

shows results of the two-hybrid system analysis in the absence of 3-aminotetrazole (3-AT), an inhibitor of the HIS3 reporter gene necessary for histidine synthesis. With reference to panel A of

FIG. 2

, diploid cells expressing the cytoplasmic tail of human ICA512 (ICA512-cyt) fused to the DNA binding protein LexA and the B8 polypeptide fused to the GAL4 activation domain survive in the absence of histidine in the media. This result suggests that the B8 olypeptide interacts with ICA512-cyt and leads to the transcription of the reporter gene HIS3.

On the contrary, the unrelated control baits lamin and MSS4 (panel A of

FIG. 2

) do not interact with the B8 polypeptide, suggesting that the B8 polypeptide does not interact with all proteins. In addition to wild type ICA512-cyt, B8 binds to the cytoplasmic tail of phogrin (phogrin-cyt), a portion of phogrin which is 74% identical to the corresponding region of ICA512. Further, B8 interacts with ICA512-cyt AD/DA, a mutant wherein alanine-877 and aspartic acid-911 of the atypical PTP-like domain of the protein are replaced with aspartic acid and alanine, respectively, both of which are present in conventional PTPs.

Panel B of

FIG. 2

shows results of the two-hybrid mating assay performed in more stringent conditions due to the presence of 2 mM 3-AT. As shown in

FIG. 2

, panel B, under these conditions, ICA512-cyt AD/DA and phogrin-cyt do not appear to bind B8, whereas an interaction still occurs in cells expressing wild type ICA512-cyt and B8 polypeptide. These data suggest that the B8 polypeptide interacts more strongly with ICA512-cyt than with ICA512-cyt AD/DA or phogrin-cyt, and that the atypical PTP domain of ICA512 is involved in this association.

FIG. 2

, panel C, shows a Western blot for ICA512-cyt (lane

1

), ICA512-cyt AD/DA (lane

2

), and phogrin-cyt (lane

3

), each expressed in combination with B8 as described above and probed with anti-LexA antibodies. As shown in panel C, in diploid yeast cells, ICA512-cyt is expressed significantly less than ICA512-cyt AD/DA and phogrin-cyt. Panel D of

FIG. 2

shows a Western blot for B8 in the same diploid yeast cells using an anti-HA antibody. This Western blot show that all diploid cells express similar amounts of B8. The results of these experiments rule out the possibility that survival of diploid yeast cells expressing ICA512-cyt and B8 in the presence of 2 mM 3-AT (

FIG. 4B

) is due to a higher level of expression of ICA512-cyt compared with ICA512-cyt AD/DA or phogrin-cyt and is consistent with the notion that B8 binds ICA512-cyt with higher affinity than ICA512-cyt AD/DA and phogrin-cyt.

The interaction of B8 with ICA512 was been confirmed biochemically by co-immunoprecipitation experiments in combination with Western blot (FIG.

3

). Briefly, the cDNAs of human ICA512 and the B8 clone were subcloned into the pRC/RSV expression vector (Invitrogen, Carlsbad, Calif.). A starting methionine and a Kozak's sequence at the 5′-end of the B8 cDNA were introduced by standard procedures using the PCR. Transient co-transfection of cultured COS cells (Gluzman, 1981) was carried out with the Ca

2+

-phosphate procedure (Chen et al., 1987; Hanson et al., 1989) by using a mixture containing 15 μg of each plasmid.

Seventy-two hours after transfection, COS cells were solubilized with 1 ml of homogenization buffer (HB) containing 2% Triton X-100 for 90 min. One confluent 10 cm dish of transfected cells was used for each immunoprecipitation. 2% Triton X-100 insoluble material was removed from the extracts by centrifugation at 15,000 g× for 30 min. After pre-clearance of the Triton X-100 soluble material with protein G-sepharose beads (50% w/vol; Pharmacia, Piscataway, N.J.) for 1 hr, 10 μl of α-ICA512 monoclonal antibody or 10 μl of the rabbit antiserum directed against βIV-spectrin were added to 1 ml Triton-X-100 extract and incubated overnight on a rocking platform at 40° C. Following the addition of 50 μl protein G-sepharose beads for 1 hr the immunocomplexes were recovered by centrifugation at 16,000×g, washed, and separated on 8% SDS-PAGE. Separated proteins were transferred onto nitrocelluose and immunoblotted with rabbit anti-ICA512 (1:1000) or anti-βIV-spectrin antibodies (1:1000) followed by goat anti-rabbit antibodies conjugated to alkaline phosphatase (1:5,000; Sigma, S. Louis, Ind.).

In the above assay, antibodies for use in the immunoblots were prepared as follows. A 21-mer synthetic peptide (CEELPRRRRPERQESVDQSEE, SEQ ID NO:8) including residues 1970-1989 of βIV-spectrin was coupled to bovine thyroglobulin and injected into rabbits to generate a polyclonal antiserum. The serum of one immunized rabbit recognized the recombinant polypeptide encoded by the B8 cDNA expressed in

E. coli

by western blotting. Anti-βIV-spectrin antibodies from this serum were affinity purified on the immunogenic peptide that had been covalently coupled to agarose beads using an AminoLink kit (Pierce, Rockford, Ill.). Anti-βIV-spectrin antibodies were eluted from the column with 0.1 N acetic acid, pH 2.5 and immediately brought back to neutral pH with 1M Tris, pH 9.0.

As shown in

FIG. 3

, pro-ICA512 appears as a triplet of ˜115 kD (bracket), whereas mature ICA512 has a molecular weight of ˜70 kD (arrow in the left panel). Two arrows in the center and right panels point to immunoprecipitated B8 at the expected molecular weight of ˜60 kD. Detection of B8 in the immunoprecipitates from co-transfected COS cells, but not from wild-type COS cells, indicates that this protein was immunoprecipitated specifically together with ICA512 by the anti-ICA512 monoclonal antibody. Likewise, ICA512 co-immunoprecipitated with B8 after incubation of detergent extracts from co-trasfected COS cells with anti-B8 antibodies (data not shown).

Having established that the B8 polypeptide interacts with the cytoplasmic domain of ICA512 by two independent assays (two-hybrid screening in yeast and co-immunoprecipitation experiments from transfected fibroblasts), the remaining 5′ end portion of the gene encoding the B8 polypeptide, i.e. the bIV-spectrin cDNA, was cloned.

To clone the 5′-end of the βIV-spectrin cDNA, a 300 base pair fragment contained within the B8 cDNA clone was amplified by PCR and labeled with [α-

32

p-dCTP] (3,000 Ci/mmol, Amersham, Arlington Heights, Ill.) using the Random Prime Labeling Kit (Amersham). This probe was used to screen 2×10

6

independent phages from a λgt-11 human brain cDNA library (Clontech, Palo Alto, Calif.). Three independent positive phages were isolated whose cDNA insert partially overlapped with the original cDNA B8 clone isolated by two-hybrid. Screenings of a λgt-10 human brain cerebellum library (Clontech, Palo Alto, Calif.) resulted in the isolation of additional 20 independent phages. Sequencing of the cDNA inserts from the isolated phages allowed the assembly of the 7,812 base pair cDNA of βIV-spectrin shown in SEQ ID NO:1 (FIG.

5

), discussed below. Automated sequencing was performed by the Keck Biotechnology Resource Laboratory at Yale University School of Medicine. DNA computer assisted analysis was executed using BLAST (Altschul et al., 1990) and SWISS-PROT (University of Geneva, Switzerland) and Lasergene software (DNASTAR Inc, Madison, Wis.).

The most significant features of the βIV-spectrin molecule are shown generally in FIG.

4

. As shown in

FIG. 4

, the partial primary sequence of the βIV-spectrin molecule includes multiple (17) spectrin-like repeats, region designated as βIV U including a unique tetrarepeat of specific amino acids, a proline-rich domain (designated as PRD), and a pleckstrin homology domain (designated as PH). These features of the primary sequence of βIV-spectrin are discussed in more detail below.

FIG. 5

shows in more detail the partial cDNA sequence (SEQ ID NO:1) and corresponding translated protein sequence (SEQ ID NO:2) of human βIV-spectrin. As shown in FIG.

5

and in SEQ ID NOS: 1 and 2, this cDNA sequence is 7,812 nucleotides in length and codes for a protein of about 2,293 amino acids having a predicted MW of approximately 252 kD. An open reading frame ranges from nucleotides 1-6,879. The primary sequence of the βIV-spectrin protein includes several significant structural features as shown in Table 1.

TABLE 1

Structural Features of the βIV-Spectrin Polypeptide

Feature

Location

Putative actin binding

residues 1-12

domain (partial)

Spectrin repeat 1

residues 13-282

Spectrin repeat 2

residues 283-624

Spectrin repeat 3

residues 625-936

Spectrin repeat 4

residues 937-1323

Spectrin repeat 5

residues 1324-1638

Spectrin repeat 6

residues 1639-1965

Spectrin repeat 7

residues 1966-2217

Spectrin repeat 8

residues 2218-2595

Spectrin repeat 9

residues 2596-2919

Spectrin repeat 10

residues 2920-3234

Spectrin repeat 11

residues 3235-3573

Spectrin repeat 12

residues 3574-3870

Spectrin repeat 13

residues 3871-4278

Spectrin repeat 14

residues 4279-4599

Spectrin repeat 15

residues 4600-4923

Spectrin repeat 16

residues 4924-5241

Spectrin repeat 17

residues 5242-5568

Beta IV repeat 1

residues 5881-5895

Beta IV repeat 2

residues 5935-5949

Beta IV repeat 3

residues 5989-6003

Beta IV repeat 4

residues 6088-6103

Proline-rich domain (PRD)

residues 6412-6432

Pleckstrin homology domain (PH)

residues 6433-6879

Stop Codon

residues 6880-6882

poly adenylation signal (pAS)

residues 7753-7759

As indicated in Table 1 above, a partial putative actin binding domain is located from residues 1-12. Seventeen consecutive spectrin repeats are located from residues 13-5568. Four repeating sequences of Glu-Arg-Gln-Glu-Ser (SEQ ID NO:3) unique to βIV-spectrin are positioned at residues 5881-5895, 5935-5949, 5989-6003, and 6088-6103. A proline-rich domain (PRD) is located from residues 6412-6432 of the βIV-spectrin protein sequence. Proline rich domains can mediate the interaction with proteins containing src-homology 3 (SH3) domain (a repeat of approximately 60 amino acids found in many proteins that mediate their assembly with proteins containing proline-rich domains), or WW domains (a domain spanning approximately 35 amino acids which bind to proteins with specific proline-rich motifs and having multiple tryptophan (W) residues).

A pleckstrin homology (PH) domain is located from residues 6433-6879 of the βIV-spectrin primary sequence. Pleckstrin homology domains can bind to proteins or phosphoinositides, and have been shown to mediate the association of proteins with phosphoinositides in membranes as described in Pawson, T. Nature 373:573-580 (1995).

Comparison of βIV-spectrin cDNA and the predicted primary amino acid sequence with publicly available sequences indicates that βIV-spectrin is a new member of the spectrin family. Other members of this family include alpha and beta isoforms of spectrin, some of which are expressed in erythroid cells, while others have a more widespread tissue distribution. βIV-spectrin has been found to be most homologous to the beta chain of non-erythroid spectrin (also known as β-fodrin), which may be involved in neurosecretion.

Screening of a human BAC genomic library (Genomic System, S. Loius, Mo.) using a 300 bp probe located within the open reading frame of the gene led to the isolation of a BAC clone (clone F614) containing the human bIV-spectrin gene. The presence of introns and exon boundaries within the bIV-spectrin gene was confirmed by automated sequencing of the isolated BAC clone F614 followed by computer assisted DNA analysis with the Genefinder Software. As shown in

FIG. 6

, the localization of the human bIV-spectrin gene (in green) was obtained by fluorescence in situ hybridization (FISH) on human chromosomes. Briefly, DNA from clone F614 was labeled with digoxigenin dUTP (Boehringher Mannheim, Indianapolis, Ind.) by nick translation. Labeled probes were combined with sheared human DNA and hybridized to normal metaphase chromosome derived from phytohemagglutinin stimulated peripheral blood lymphocytes from a male donor in a solution containing 50% formamide, 10% dextran sulfate and 2× SSC. Specific hybridization signals were detected by incubating the hybridized slides in fluoresceinated antidigoxigenin antibodies followed by counterstaining with DAPI. The initial experiment resulted in specific labeling of the mid long arm of a group F chromosome. A second set of experiments was conducted in which a genomic clone from the E2A locus (19p13.3) was co-hybridized with clone F614. This experiment resulted in the specific labeling of the short and long arms of chromosome 19. Measurements of 10 specifically hybridized chromosomes 19 demonstrated that F614 is located at a position which is 41% of the distance from the centromere to the telomere of chromosome arm 19q, an area that corresponds to band 19q13.13. A total of 80 metaphase cells were analyzed for each clone with 74 exhibiting specific labeling.

To determine the expression of βIV-spectrin in various tissues, a commercial Multi Tissue Northern blot (Clontech, Palo Alto, Calif.) was probed with a ˜700 base pair

32

p-labeled cDNA probe located within the open reading frame (ORF-1) of βIV-spectrin according to the manufacturer's instructions. Next, the same blot was stripped and reprobed with a ˜700 base pair

32

p-labeled cDNA probe located within the 3′-untranslated region (3′-UTR) of the βIV-spectrin gene. Both probes were obtained by PCR using the B8 cDNA as a template.

FIG. 7

shows Northern blot analysis of poly A

+

RNA from human tissues with probes in both the open reading frame (ORF-1) and the 3′-untranslated region (UTR) of βIV-spectrin. As shown in

FIG. 7

, both probes hybridized with two transcripts of ˜4.7 kB and 9.5 kB that are predominantly expressed in brain. These data strongly suggest that both transcripts derived from a single gene. Two transcripts of ˜4.7 Kb and ˜7.5 Kb were detected after long exposure in human heart, skeletal muscle and kidney, while in human pancreas the smaller transcript migrated slightly faster than in the other tissues (data not shown). As a control, the same nitrocellulose filter was probed with an actin probe (FIG.

7

).

Since islets represent ˜3% of the total weight of pancreas, islet specific transcripts are significantly under-represented in commercially available RNA preparations. To overcome this limit, a Northern blot was performed on polyA+ RNA isolated from human islets (

FIG. 8

, NB left panel). Briefly, poly A+ RNA was isolated from 40,000 human islets (kindly provided by the Islet Isolation and Distribution Program at University of Miami, Fla.) using a poly A+ RNA isolation kit (Qiagen, Valencia, Calif.) according to the manufacturer's instructions. 2 μg poly A+RNA was run on a agarose gel containing 2% formaldehyde, blotted overnight on nitrocellulose and probed with the

32

p-labeled ORF-1 probe as described above. As shown in

FIG. 8

(NB, left panel), βIV-spectrin mRNA is enriched in human islet cells. Specifically, two major RNA transcripts of 4.2 Kb and 8.3 Kb were detected. The slightly faster migration of these transcripts compared to the transcripts detected in human brain may be accounted by differential tissue-specific alternative splicing of the gene.

Protein expression of βIV-spectrin in human islets was further assesed by Western blot experiments as shown in

FIG. 8

(WB, right panel). Approximately 40,000 human pancreatic islets (Human Islet Isolation and Distribution Program, University of Miami, Fla.) were solubilized in 10 mM HEPES, pH 7.4, 150 mM NaCl, 1% Triton X-100, 1 mM phenylmethyl-sulfonylfluoride (PMSF), 10 mM benzamidine, 1 μg/ml aprotinin, 1 μg/ml leupeptin, 1 μg/ml pepstatin A, and 1 μg/ml antipain. Cell extracts were centrifuged for at 100,000×g for 1 hour. Triton X-100 insoluble pellets were resuspended in Laemmli buffer with 2% SDS and separated by 6% SDS-polyacrylamide gel electrophoresis. After transfer onto nitrocellulose, proteins were immunoblotted with affinity purified anti-βIV-spectrin antibodies (1:1000) followed by peroxidase conjugated goat anti rabbit IgG (1:5,000; Sigma, St. Louis, Mo.) and prepared as described above. The signal was detected using the SuperSignal reagents (Pierce, Rockford, Ill.) for enhanced chemiluminescence according to the manufacturer's protocol.

Anti-βIV-spectrin affinity purified antibodies recognize two major protein doublets of ˜230 kD and 150 kD (

FIG. 8

WB, right panel). These two proteins subsets may represent the products of the two main transcripts detected by Northern blot. The size of the larger species is comparable with that of other beta spectrins, which also migrate at ˜230 kD by SDS-PAGE.

FIG. 9

shows confocal microscopy on sections of rat pancreas stained with affinity purified βIV spectrin antibodies. Double immunofluorescence on 12 μm cryostat tissue sections of rat pancreas was performed as described previously (Cameron et al., 1991). Briefly, the tissue sections were incubated for 30 minutes at room temperature in 20 mM phosphate buffer, pH 7.4 containing 16% goat serum, 0.3% Triton X-100 and 0.45 M NaCl (goat serum dilution buffer, GSDB). Next, sections were incubated for 2 hrs with a mixture including either the affinity purified anti-βIV-spectrin antibodies (1:500 dilution) or a rabbit antiserum against αII-spectrin (1:100, Chemicon, Temecula, Calif.) and one of the following mouse monoclonal antibodies: anti-insulin, (1:100, Sigma, St. Louis, Mo.); anti-glucagon (1:100, Sigma, St. Louis, Mo.), or anti-ICA512 (1:200), each prepared as described above. All antibody dilutions were made in GSDB. After multiple washing with phosphate buffer, the sections were incubated in a mixture of goat rabbit (1:100) and goat-anti mouse (1:100) IgG coupled to FITC and Texas red, respectively.

Rat insulinoma INS-1 cells were grown to ˜50% confluency on glass-coverslips in DMEM with 10% fetal bovine serum. Before immunostaining, cells were fixed with 4% paraformaldehyde in PBS at room temperature for 30 minutes. Immunolabeling for αII-spectrin and insulin was performed as described above. Confocal microscopy on immunostained tissue sections and cultured cells was performed using a Biorad MRC-1040 system equipped with a krypton—argon laser attached to a Zeiss Axiovert microscope (Zeiss, Thornwood, N.Y.). Acquired images were processed with Adobe Photoshop as described previously (Xu et al., 1992).

The results shown in

FIG. 9

demonstrate that βIV-spectrin, similar to ICA512 (top right panel) and phogrin (not shown), is enriched in both α-cells (counterstained for glucagon) and β-cells (counterstained for insulin) of pancreatic islets. Low levels of immunoreactivity are detectable in the surrounding exocrine pancreas.

βIV-spectrin may be suitable for detecting the presence of anti-βIV-spectrin autoantibodies in humans. The methods of the present invention employ purified βIV-spectrin ligand for the anti-βIV-spectrin autoantibodies for detection of such autoantibodies in serum samples. The purified βIV-spectrin ligand will usually be an isolated form, but may also be a βIV-spectrin fragment or other peptide which defines an epitopic binding site capable of specifically binding the anti-βIV-spectrin autoantibodies. It will be appreciated that knowledge of the DNA sequence of the βIV-spectrin gene as well as the amino acid sequence of βIV-spectrin allows identification and preparation of a variety of synthetic peptide compositions which can be utilized as the purified ligand of the present invention. Additionally, the methods of the present invention could utilize anti-idiotypic antibodies capable of specifically binding the anti-βIV-spectrin autoantibodies.

The purified ligand of the present invention may be natural, i.e., intact βIV-spectrin or fragments thereof as described above, isolated from suitable sources. Usually, natural polypeptides will be isolated from CNS cells (e.g., brain tissue) where βIV-spectrin is abundant.

Natural polypeptides may be isolated by conventional techniques such as affinity chromatography. Conveniently, polyclonal or monoclonal antibodies may be raised against previously purified βIV-spectrin and may be utilized to prepare a suitable affinity column by well known techniques. Such techniques are taught, for example, in Hudson and Hay,

Practical Immunology

, Blackwell Scientific Publications, Oxford, United Kingdom, 1980, Chapter 8. Usually, an intact form of βIV-spectrin will be obtained by such isolation techniques. If peptide fragments are desired, they may be obtained by chemical or enzymatic cleavage of the intact molecule.

As an alternative to isolating intact βIV-spectrin from natural sources, it will be possible to prepare synthetic βIV-spectrin proteins and polypeptides based on the sequence of βIV-spectrin which are disclosed herewith. Alternatively, cDNA expression libraries may be screened for a desired form of βIV-spectrin using βIV-spectrin antibodies which are available or may be prepared as described herein.

Synthetic proteins and polypeptides may be produced by either of two general approaches. First, polypeptides having up to about 150 amino acids, usually having fewer than about 100 amino acids, and more usually having fewer than about 75 amino acids, may be synthesized by the well known Merrifield solid-phase synthesis method where amino acids are sequentially added to a growing chain. See, Merrifield, B., J. Am. Chem. Soc. 85:2149-2156 (1963). Apparatus for automatically synthesizing such polypeptides using the solid-phase methodology are now commercially available from numerous suppliers, such as Applied Biosystems, Foster City, Calif.

The second and preferred method for synthesizing the proteins and polypeptides of the present invention involves the expression in cultured mammalian cells of recombinant DNA molecules encoding the desired βIV-spectrin gene portion thereof. The use of mammalian expression system, such as Chinese hamster ovary (CHO) cells, can provide for post-translational modification of the proteins and polypeptides which enhances the immunological similarity of the synthetic products with the native forms of βIV-spectrin. The βIV-spectrin gene may itself be natural or synthetic, with the natural gene obtainable from cDNA or genomic libraries using degenerate probes based on the known amino acid sequence set forth herewith. Alternatively, polynucleotides may be synthesized based on the DNA sequence by well known techniques. For example, single-stranded DNA fragments may be prepared by the phosphoramidite method described by Beaucage and Carruthers in Tetrahedron Lett. 22:1859-1862 (1981). A double-stranded fragment may then be obtained by synthesizing the complementary strand and annealing the strands together under appropriate conditions or by adding the complementary strand using DNA polymerase with an appropriate primer sequence.

The natural or synthetic DNA fragments coding for the βIV-spectrin protein or fragment will then be incorporated in DNA constructs capable of introduction to and expression in an in vitro mammalian cell culture. Usually, the DNA constructs will be capable of replicating in prokaryotic hosts in order to facilitate initial manipulation and multiplication of the construct. After a sufficient quantity of the construct has been obtained, they will be introduced and usually integrated into the genome of cultured mammalian or other eukaryotic cell lines.

DNA constructs suitable for introduction to bacteria or yeast will include a replication system recognized by the host, the βIV-spectrin DNA fragment encoding the desired protein or polypeptide product, transcriptional and translational initiation and regulatory sequences joined to the 5′-end of the structural DNA sequence, and transcriptional and translational termination regulatory sequences joined to the 3′-end of the structural sequence. The transcriptional regulatory sequences will include a heterologous promoter which is recognized by the host.

Conveniently, available cloning vectors which include the replication system and transcriptional and translational regulatory sequences together with an insertion site for the βIV-spectrin DNA sequence may be employed. For transformation of mammalian and other eukaryotic cell lines, co-transfection of the cell lines in the presence of suitable marker, such as DHFR gene, may be employed. Transfection may also be accomplished using chemical or electroporation techniques.

The ligands of the present invention are advantageously utilized in a substantially pure form, that is, typically being at least about 50% w/w (weight/weight) purity, as well as being substantially free from interfering proteins and contaminants. Preferably, the ligands will be isolated or synthesized in a purity of at least about 80% w/w and, more preferably in at least about 95% w/w purity. Using conventional protein purification techniques, homogeneous peptides of at least 99% w/w can be obtained. For example, the proteins may be purified by use of antibodies specific for the βIV-spectrin polypeptide using immunoadsorbent affinity chromatography. Such affinity chromatography is performed by first linking the antibodies to a solid phase support and then contacting the linked antibodies with the source of the ligand polypeptides, e.g., lysates of CNS cells or cells which have been recombinantly modified to produce βIV-spectrin, or of supernatants of cells which have been recombinantly modified to secrete βIV-spectrin when cultured.

For use in purification, antibodies to βIV-spectrin may be obtained by injecting nucleic acids or polypeptides corresponding to βIV-spectrin or βIV-spectrin fragments into a wide variety of vertebrates in accordance with conventional techniques. Suitable vertebrates include mice, rats, sheep, and goats. Usually, the animals are bled periodically with successively bleeds having improved titer and specificity. The antigens may be injected intramuscularly, interperitoneally, subcutaneously, or the like. Usually, vehicles are employed such as a complete or incomplete Freund's adjuvant. Preferably, monoclonal antibodies can be prepared by well-known techniques. In particular, monoclonal FAB fragments may be produced in

E. coli

by the method of Ruse et al. (Science 246:1275-1281 (1989)).

The assays of the present invention will detect the presence of βIV-spectrin in patient sera. It has been found that diabetic and prediabetic patients will usually have autoantibodies to βIV-spectrin. Thus, the preferred assay of the present invention will be able to detect the presence of antibodies reactive with βIV-spectrin. A negative results (i.e., no reaction) will indicate that the patient is neither diabetic nor prediabetic. A positive result will indicate that the patient is diabetic or prediabetic.

Assays according to the present invention typically rely on exposing the purified ligand to a serum sample and detecting specific binding between the ligand and anti-βIV-spectrin autoantibodies which may be present in the serum. Binding between the autoantibodies and purified ligand indicates that the autoantibodies are present, and is diagnostic of a diabetic or prediabetic condition in the patient. Alternatively, such assays can be used to monitor the condition of a patient who has undergone a pancreatic islet cell transplant, where the presence of the anti-βIV-spectrin autoantibodies indicates an adverse immune response to the transplanted cells. The particular assay protocol chosen is not critical, and it is necessary only that the assay be sufficiently sensitive to detect a threshold level of the autoantigen which is considered to be positive.

Assays according to the present invention will be useful for identifying patients who are either prediabetic, i.e., who have circulating autoantibodies to the anti-βIV-spectrin autoantigen but who have not yet suffered sufficient damage to the insulin-producing β-cell to be clinically identified as having IDDM, or who suffer from clinical IDDM. The assays will also be useful for monitoring the effect of immunotherapy to block or prevent autoimmune reactions to the β-cell and for monitoring the progress of the disease from pre-diabetes to clinical diabetes and will be particularly useful for monitoring the status of transplanted pancreatic β-cells in diabetic patients who have undergone an islet cell graft.

Suitable assays include both solid phase (heterogeneous) and non-solid phase (homogeneous) protocols. The assay may be run using competitive or non-competitive formats, and using a wide variety of labels, such as radioisotopes, enzymes, fluorescers, chemiluminescers, spin labels, and the like. A majority of suitable assays rely on heterogeneous protocols where the ligand is bound to a solid phase which is utilized to separate the ligand-autoantibody complex which forms when autoantibody is present in the serum sample. A particular advantage of using a purified ligand is that it facilitates the preparation of a solid phase for use in the assay. That is, the ligand may be conveniently immobilized on a variety of solid phases, such as dipsticks, particulates, microspheres, magnetic particles, test tubes, microtiter wells, and the like.

The solid phase is exposed to the serum sample so that the autoantibody, if any, is captured by the ligand. By then removing the solid phase from the serum sample, the captured autoantibodies can be removed from unbound autoantibodies and other contaminants in the serum sample. The captured autoantibody may then be detected using the non-competitive “sandwich” technique where labeled ligand for the autoantibody is exposed to the washed solid phase. Alternatively, competitive formats rely on the prior introduction of soluble, labeled autoantibody to the serum sample so that labeled and unlabelled forms may compete for binding to the solid phase. Such assay techniques are well known and well described in both the patent and scientific literature. Exemplary immunoassays which are suitable for detecting the autoantibodies in serum include those described in U.S. Pat. Nos. 3,791,932; 3,817,837; 3,839,153; ,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; and 4,098,876, the disclosures of which are incorporated herein by reference.

Particularly preferred are sensitive enzyme-linked immunosorbent assay (ELISA) methods which are described in detail in U.S. Pat. Nos. 3,791,932; 3,839,153; 3,850,752; 3,879,262; and 4,034,074. Such ELISA assays can provide measurement of very low titers of the autoantibodies.

According to the preferred ELISA technique, the purified ligand is bound either covalently or non-covalently to a solid surface. The solid surface is exposed to the serum sample where autoantibody present in the sample is captured and bound. Typically, the ligand on the solid phase will be present in excess so that the entire quantity of autoantibody may be bound. After separating the solid phase and washing its surface, the solid phase can be exposed to labeled reagent capable of specifically binding the captured autoantibody. The labeled reagent may be labeled purified ligand, or may be other ligand capable of binding to the autoantibody, e.g., labeled anti-human antibody. In this way, label is bound to the solid phase only if autoantibody was present in the serum sample. The enzyme labels may be detected by conventional visualization techniques, i.e., production of a colored dye, chemiluminescence, fluorescence, or the like.

A second preferred embodiment comprises radioimmunoassays (RIA) which are performed using a solid phase which has been prepared as described above. The solid phase is exposed to the serum sample in the presence of radiolabeled autoantibodies which can compete for binding to the immobilized ligand. In this way, the amount of radiolabel bound to the solid phase will be inversely proportional to the amount of autoantibodies initially present in the serum sample. After separation of the solid phase, non-specifically bound radiolabel can be removed by washing, and the amount of radiolabel bound to the solid phase determined. The amount of bound radiolabel, in turn, can be related to the amount of autoantibodies initially present in the sample.

Purified ligand of the present invention can be incorporated as components of pharmaceutical compositions useful to attenuate, inhibit, or prevent the destruction of pancreatic β-cells associated with the onset of insulin-dependent diabetes mellitus. The compositions should contain a therapeutic or prophylactic amount of at least one purified ligand according to the present invention in a pharmaceutically-acceptable carrier. The pharmaceutical carrier can be any compatible, non-toxic substance suitable to deliver the peptides to the patient. Sterile water, alcohol, fats, waxes, and inert solids may be used as the carrier. Pharmaceutically-acceptable adjuvants, buffering agents, dispersing agents, and the like, may also be incorporated into the pharmaceutical compositions. Such compositions can contain nucleic acids or a single polypeptide encoded by the βIV-spectrin gene, or may contain two or more polypeptides according to the present invention in the form of a “cocktail”. In one embodiment, the purified ligand binds to a protein having an amino acid sequence comprising at least one sequence of Glu-Arg-Gln-Glu-Ser (SEQ ID NO:3).

It is presently believed by the inventors herein that the destruction of pancreatic β-cells in IDDM is a cellular autoimmune response. Thus, the pharmaceutical compositions should be suitable for inhibiting such a response. In particular, it may be desirable to couple the purified ligands of the present invention to immunoglobulins, e.g., IgG, or to lymphoid cells from the patient being treated in order to promote tolerance. Such an approach is described in Bradley-Mullen,

Activation of Distinct Subsets of T Suppressor Cells with Type III Pneumococcal Polysaccharide Coupled to Syngeneic Spleen Cells

, in: IMMUNOLOGICAL TOLERANCE TO SELF AND NON-SELF, Buttisto et al., eds., Annals N.Y. Acad. Sci., Vol. 392, pp. 156-166 (1982). Alternatively, the peptides may be modified to maintain or enhance binding to the MHC while reducing or eliminating binding to the associated T-cell receptor. In this way, the modified βIV-spectrin peptides may compete with natural βIV-spectrin to inhibit helper T-cell activation and thus inhibit the immune response In all cases, care should be taken that administration of the pharmaceutical compositions of the present invention does not potentiate the autoimmune response.

The pharmaceutical compositions just described are useful for parenteral administration. Preferably, the compositions will be administered parenterally, i.e., subcutaneously, intramuscularly, or intravenously. Thus, the invention provides compositions for parenteral administration to a patient, where the compositions comprise a solution or dispersion of the polypeptides in an acceptable carrier, as described above. The concentration of the nucleic acids or polypeptides in the pharmaceutical composition can vary widely, i.e., from less than about 0.1% by weight, usually being at least about 1% by weight in as much as 20% by weight or more. Typical pharmaceutical composition for intramuscular injection would be made up to contain, for example, 1 ml of sterile buffered water and 1 to 100 μg of the purified ligand of the present invention. A typical composition for intravenous infusion could be made up to contain 100 to 500 ml of sterile Ringer's solution and 100 to 500 mg of the purified ligand. Actual methods for preparing parenterally administrable compositions are well known in the art and described in more detail in various sources, including, for example,

Remington's Pharmaceutical Science,

15th Edition, Mack Publishing Company, Easton, Pa. (1980), which is incorporated herein by reference.

The pharmaceutical nucleic acid or polypeptide compositions of the present invention may be administered for prophylactic treatment of prediabetic individuals identified by the assay methods of the present invention or for therapeutic treatment of individuals suffering from insulin-dependent diabetes mellitus but having a substantial residual mass of pancreatic β-cells. For therapeutic applications, the pharmaceutical compositions are administered to a patient suffering from established diabetes in an amount sufficient to inhibit or prevent further β-cell destruction. For individuals susceptible to diabetes, the pharmaceutical compositions are administered prophylactically in an amount sufficient to either prevent or inhibit immune destruction of the β-cells. An amount adequate to accomplish this is defined as “therapeutically-effective dose”. Such effective dosage will depend on the severity of the autoimmune response and on the general state of the patient's health, but will generally range from about 1 to 500 mg of purified ligand per kilogram of body weight, with dosages of from about 5 to 25 mg per kilogram being more commonly employed.

The therapeutic methods of the present invention comprise administering the pharmaceutical compositions of the present invention in the amounts and under the circumstances described above.

αII spectrin may also become a candidate for targeted therapy of insulin dependent diabetes mellitus, and has been identified as being expressed in pancreatic beta cells (Haneji et al., Science 276:804 (1997); Yanagi et al., Eur. J. Immunol. 28:3336 (1998)), FIG.

10

. In

FIG. 10

, immunocytochemistry and confocal microscopy were performed as described above for FIG.

9

.

The top row of images in

FIG. 10

shows expression of αII spectrin in pancreatic islets of a 6 weeks old non-obese diabetic (NOD) mouse as revealed by double immunocytochemistry with a rabbit antibody directed against αII spectrin (in green, left panel) and guinea pig anti-insulin antibody, (in red, middle panel). The merge of these two panels is shown the on the right. As shown in

FIG. 10

, alpha II spectrin is prominently expressed in the insulin-producing beta cells of the pancreatic islets. As shown in other cell types, the protein is primarily localized beneath the plasma membrane and mostly at regions of cell—cell contact.

The bottom row of images shown in

FIG. 10

show double immunocytochemistry for αII spectrin (in green, left panel) and insulin (red, middle panel) in rat insulinoma INS-1 cells in culture. The merge of these two panels is shown in the right panel. The data shown in

FIG. 10

illustrates αII spectrin is enriched in pancreatic beta cells.

While the invention has been described above with reference to specific embodiments thereof, it is apparent that many changes, modifications, and variations can be made without departing from the inventive concept disclosed herein. Accordingly, it is intended to embrace all such changes, modifications, and variations that fall within the spirit and broad scope of the appended claims. All patent applications, patents, and other publications cited herein are incorporated by reference in their entirety.

# SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 8

<210> SEQ ID NO 1

<211> LENGTH: 7812

<212> TYPE: DNA

<213> ORGANISM: Human

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1)...(6879)

<221> NAME/KEY: unsure

<222> LOCATION: (100)...(102)

<221> NAME/KEY: unsure

<222> LOCATION: (1021)...(1023)

<221> NAME/KEY: unsure

<222> LOCATION: (2266)...(2268)

<400> SEQUENCE: 1

cta ctg gtc tct ttc tac cac tat ttc tcc aa

#g atg aaa gct ctg gct 48

Leu Leu Val Ser Phe Tyr His Tyr Phe Ser Ly

#s Met Lys Ala Leu Ala

1 5

# 10

# 15

gtg gag ggg aaa gcc gta tcg gga agg gcc tg

#g atc cac cgc acc gtg 96

Val Glu Gly Lys Ala Val Ser Gly Arg Ala Tr

#p Ile His Arg Thr Val

20

# 25

# 30

ggc ntc atc agc aat cag aaa ttt gcc aac tc

#c tta agt ggg gtg cag 144

Gly Xaa Ile Ser Asn Gln Lys Phe Ala Asn Se

#r Leu Ser Gly Val Gln

35

# 40

# 45

cag caa ctc cag gct ttc acg gcc tat tgc ac

#g ctg gag aag cct gtc 192

Gln Gln Leu Gln Ala Phe Thr Ala Tyr Cys Th

#r Leu Glu Lys Pro Val

50

# 55

# 60

aag ttc cag gag aag ggg aac cta gag gtg ct

#g ctc ttc agc atc cag 240

Lys Phe Gln Glu Lys Gly Asn Leu Glu Val Le

#u Leu Phe Ser Ile Gln

65

# 70

# 75

# 80

agc aaa ctg cgt gcc tgc aac cgt cgc ctc tt

#t gtg cct cgg gag ggc 288

Ser Lys Leu Arg Ala Cys Asn Arg Arg Leu Ph

#e Val Pro Arg Glu Gly

85

# 90

# 95

tgt ggc atc tgg gat att gac aag gca tgg gg

#t gag ctg gag aag gct 336

Cys Gly Ile Trp Asp Ile Asp Lys Ala Trp Gl

#y Glu Leu Glu Lys Ala

100

# 105

# 110

gag cat gag cgg gag gct gcc cta cgg gct ga

#g ctg att cgg cag gag 384

Glu His Glu Arg Glu Ala Ala Leu Arg Ala Gl

#u Leu Ile Arg Gln Glu

115

# 120

# 125

aag ctg gaa cta ctg gca cag agg ttt gac ca

#c aag gtg gct atg agg 432

Lys Leu Glu Leu Leu Ala Gln Arg Phe Asp Hi

#s Lys Val Ala Met Arg

130

# 135

# 140

gag agc tgg ctg aat gag aac cag cgt ctg gt

#c tcc cag gac aac ttt 480

Glu Ser Trp Leu Asn Glu Asn Gln Arg Leu Va

#l Ser Gln Asp Asn Phe

145 1

#50 1

#55 1

#60

ggg tat gag ctg ccc gca gtg gag gca gcc at

#g aag aaa cac gaa gcg 528

Gly Tyr Glu Leu Pro Ala Val Glu Ala Ala Me

#t Lys Lys His Glu Ala

165

# 170

# 175

atc gag gca gac att gcg gcc tac gag gag cg

#g gtg cag ggt gtg gcg 576

Ile Glu Ala Asp Ile Ala Ala Tyr Glu Glu Ar

#g Val Gln Gly Val Ala

180

# 185

# 190

gag ctg gcc cag gca ttg gca gcc gaa ggc ta

#c tac gat atc cgg cgg 624

Glu Leu Ala Gln Ala Leu Ala Ala Glu Gly Ty

#r Tyr Asp Ile Arg Arg

195

# 200

# 205

gtg gca gcc cag cgt gac agc gtc ctg cgc ca

#g tgg gcc ctg cta act 672

Val Ala Ala Gln Arg Asp Ser Val Leu Arg Gl

#n Trp Ala Leu Leu Thr

210

# 215

# 220

ggg ctt gtg ggt gcc cgg cgg aca cga ctt ga

#g cag aac ctt gcc ctg 720

Gly Leu Val Gly Ala Arg Arg Thr Arg Leu Gl

#u Gln Asn Leu Ala Leu

225 2

#30 2

#35 2

#40

cag aag gtc ttc cag gag atg gtg tac atg gt

#g gac tgg atg gag gag 768

Gln Lys Val Phe Gln Glu Met Val Tyr Met Va

#l Asp Trp Met Glu Glu

245

# 250

# 255

atg cag gct cag ctg ctg tcc cgg gag tgt gg

#g cag cac ctg gtg gag 816

Met Gln Ala Gln Leu Leu Ser Arg Glu Cys Gl

#y Gln His Leu Val Glu

260

# 265

# 270

gca gac gac ctg ttg cag aag cat gga ctg ct

#g gag gga gac att gcc 864

Ala Asp Asp Leu Leu Gln Lys His Gly Leu Le

#u Glu Gly Asp Ile Ala

275

# 280

# 285

gcc cag agc gag cgg gtg gag gct ctc aat gc

#c gct gcc ctg cgc ttc 912

Ala Gln Ser Glu Arg Val Glu Ala Leu Asn Al

#a Ala Ala Leu Arg Phe

290

# 295

# 300

tcc cag ccc tgc gac ccg cag gtc atc tgc aa

#c cgc gtg aac cac gtg 960

Ser Gln Pro Cys Asp Pro Gln Val Ile Cys As

#n Arg Val Asn His Val

305 3

#10 3

#15 3

#20

cac ggc tgc ctg gcg gag ctg cag gag cag gc

#a gcg cgg cga cgc gcg 1008

His Gly Cys Leu Ala Glu Leu Gln Glu Gln Al

#a Ala Arg Arg Arg Ala

325

# 330

# 335

gag ctg gag gct tcn cgg agc ctg tgg gcg ct

#g ctg cag gag ctg gag 1056

Glu Leu Glu Ala Xaa Arg Ser Leu Trp Ala Le

#u Leu Gln Glu Leu Glu

340

# 345

# 350

gag gcc gag agc tgg gcg cgc gac aag gag cg

#t ctc ctg gag gct gcg 1104

Glu Ala Glu Ser Trp Ala Arg Asp Lys Glu Ar

#g Leu Leu Glu Ala Ala

355

# 360

# 365

ggc ggc ggc ggt gcg gcg ggc gca gcg ggc gc

#a gcg gga aca gcg ggc 1152

Gly Gly Gly Gly Ala Ala Gly Ala Ala Gly Al

#a Ala Gly Thr Ala Gly

370

# 375

# 380

ggc gcg cat gac ctg tcc agc aca gcg cgc ct

#c ctg gcc cag cac aag 1200

Gly Ala His Asp Leu Ser Ser Thr Ala Arg Le

#u Leu Ala Gln His Lys

385 3

#90 3

#95 4

#00

atc ctg cag ggc gag ctg ggc ggg cgg cga gc

#g tcg ctg cag cag gcc 1248

Ile Leu Gln Gly Glu Leu Gly Gly Arg Arg Al

#a Ser Leu Gln Gln Ala

405

# 410

# 415

ctg cgg tgt ggc gag gag ctg gtt gcg gcc gg

#c ggt gcc gtc ggc ccg 1296

Leu Arg Cys Gly Glu Glu Leu Val Ala Ala Gl

#y Gly Ala Val Gly Pro

420

# 425

# 430

gga gca gac acc gtg cac ctg gta ggc ctg gc

#g gag cgc gcg gcg agc 1344

Gly Ala Asp Thr Val His Leu Val Gly Leu Al

#a Glu Arg Ala Ala Ser

435

# 440

# 445

gcc cgg cgc cgc tgg cag agg ctg gaa gag gc

#g gcg gcg cgg cga gag 1392

Ala Arg Arg Arg Trp Gln Arg Leu Glu Glu Al

#a Ala Ala Arg Arg Glu

450

# 455

# 460

cgg cgg ctg cag gag gcg cgg gcg ctg cac ca

#g ttc ggc gct gac ctc 1440

Arg Arg Leu Gln Glu Ala Arg Ala Leu His Gl

#n Phe Gly Ala Asp Leu

465 4

#70 4

#75 4

#80

gac ggg ctg ctg gac tgg ctt cgc gac gct ta

#c cgc ctg gca gcc gcc 1488

Asp Gly Leu Leu Asp Trp Leu Arg Asp Ala Ty

#r Arg Leu Ala Ala Ala

485

# 490

# 495

ggt gac ttc ggc cac gac gaa gct tcc agc cg

#c cgc ctg gcg cgc cag 1536

Gly Asp Phe Gly His Asp Glu Ala Ser Ser Ar

#g Arg Leu Ala Arg Gln

500

# 505

# 510

cac cgc gcg ctc acc ggg gag gtg gag gca ca

#t cgc ggg ccc gtg agc 1584

His Arg Ala Leu Thr Gly Glu Val Glu Ala Hi

#s Arg Gly Pro Val Ser

515

# 520

# 525

ggc ctg cgg cgc cag ctg gcg aca ctc ggg gg

#t gcc agt ggc gca ggg 1632

Gly Leu Arg Arg Gln Leu Ala Thr Leu Gly Gl

#y Ala Ser Gly Ala Gly

530

# 535

# 540

cca ctg gtg gtg gcg ctg cag gtg cgc gtg gt

#g gaa gca gag cag ttg 1680

Pro Leu Val Val Ala Leu Gln Val Arg Val Va

#l Glu Ala Glu Gln Leu

545 5

#50 5

#55 5

#60

ttc gct gag gtg acc gaa gtg gcg gcg ctg ag

#g cgc cag tgg ctg cgg 1728

Phe Ala Glu Val Thr Glu Val Ala Ala Leu Ar

#g Arg Gln Trp Leu Arg

565

# 570

# 575

gac gcg ctc gct gtc tac cgc atg ttt ggc ga

#g gtg cac gcg tgt gag 1776

Asp Ala Leu Ala Val Tyr Arg Met Phe Gly Gl

#u Val His Ala Cys Glu

580

# 585

# 590

ctg tgg atc ggc gag aag gag caa tgg ctg ct

#c tcc atg cgt gtg ccg 1824

Leu Trp Ile Gly Glu Lys Glu Gln Trp Leu Le

#u Ser Met Arg Val Pro

595

# 600

# 605

gat tca ctc gac gac gtc gag gtg gtg cag ca

#c cga ttc gag agc ctg 1872

Asp Ser Leu Asp Asp Val Glu Val Val Gln Hi

#s Arg Phe Glu Ser Leu

610

# 615

# 620

gac caa gag atg aac agc ctg atg ggc cgc gt

#t ctg gac gtg aac cac 1920

Asp Gln Glu Met Asn Ser Leu Met Gly Arg Va

#l Leu Asp Val Asn His

625 6

#30 6

#35 6

#40

aca gtc cag gag ctg gtg gaa gga ggc cac cc

#c agt tca gat gag gtg 1968

Thr Val Gln Glu Leu Val Glu Gly Gly His Pr

#o Ser Ser Asp Glu Val

645

# 650

# 655

cgt tcc tgc cag gac cac ctc aac agc agg tg

#g aac cgc atc gtg gag 2016

Arg Ser Cys Gln Asp His Leu Asn Ser Arg Tr

#p Asn Arg Ile Val Glu

660

# 665

# 670

cta gtg gaa cag cgc aaa gag gaa atg agc gc

#g gtg ctg ctg gtg gag 2064

Leu Val Glu Gln Arg Lys Glu Glu Met Ser Al

#a Val Leu Leu Val Glu

675

# 680

# 685

aac cac gtg ctg gag gtg gcc gag gtg cgc gc

#c cag gtg cgt gag aag 2112

Asn His Val Leu Glu Val Ala Glu Val Arg Al

#a Gln Val Arg Glu Lys

690

# 695

# 700

cgg aga gct gtg gag agc gcg ccc cgg gcc gg

#c ggc gcc ctg cag tgg 2160

Arg Arg Ala Val Glu Ser Ala Pro Arg Ala Gl

#y Gly Ala Leu Gln Trp

705 7

#10 7

#15 7

#20

cgt ctt agc ggc cta gag gcc gct ctg cag gc

#g ctg gag ccg cgc cag 2208

Arg Leu Ser Gly Leu Glu Ala Ala Leu Gln Al

#a Leu Glu Pro Arg Gln

725

# 730

# 735

gcg gcc ctt ctg gag gag gca gcc ctg ctg gc

#t gag cgc ttc ccg gcg 2256

Ala Ala Leu Leu Glu Glu Ala Ala Leu Leu Al

#a Glu Arg Phe Pro Ala

740

# 745

# 750

cag gcg gcg ngg ctg cac cag ggc gcg gag ga

#g ctg ggc gcc gag tgg 2304

Gln Ala Ala Xaa Leu His Gln Gly Ala Glu Gl

#u Leu Gly Ala Glu Trp

755

# 760

# 765

ggc gcg cta gct agc gcg gct cag gcc tgc gg

#c gag gcg gtg gcg gca 2352

Gly Ala Leu Ala Ser Ala Ala Gln Ala Cys Gl

#y Glu Ala Val Ala Ala

770

# 775

# 780

gca ggg cgc ctg cag cgc ttc cta cat gac ct

#c gac gct ttc ctg gac 2400

Ala Gly Arg Leu Gln Arg Phe Leu His Asp Le

#u Asp Ala Phe Leu Asp

785 7

#90 7

#95 8

#00

tgg ctc gtg cgc gcc cag gag gcg gcg ggc gg

#c agc gag ggg ccc ctg 2448

Trp Leu Val Arg Ala Gln Glu Ala Ala Gly Gl

#y Ser Glu Gly Pro Leu

805

# 810

# 815

ccc aac agc cta gaa gag gcg gac gcg ctg ct

#g gcg cgc cac gct gcg 2496

Pro Asn Ser Leu Glu Glu Ala Asp Ala Leu Le

#u Ala Arg His Ala Ala

820

# 825

# 830

ctc aag gag gag gtg gac cag cgc gag gaa ga

#c tat gct cgc atc gtg 2544

Leu Lys Glu Glu Val Asp Gln Arg Glu Glu As

#p Tyr Ala Arg Ile Val

835

# 840

# 845

gcg gcc agc gag gcg ctg ctg gcc gcc gac gg

#c gca gag ctg ggc ccg 2592

Ala Ala Ser Glu Ala Leu Leu Ala Ala Asp Gl

#y Ala Glu Leu Gly Pro

850

# 855

# 860

ggc ctg gca cta gac gag tgg ctg cca cac ct

#c gaa ctt ggc tgg cat 2640

Gly Leu Ala Leu Asp Glu Trp Leu Pro His Le

#u Glu Leu Gly Trp His

865 8

#70 8

#75 8

#80

aaa ctg ctc ggc ttg tgg aag gcg cgc agg aa

#g gcg ctg gtc cag gcg 2688

Lys Leu Leu Gly Leu Trp Lys Ala Arg Arg Ly

#s Ala Leu Val Gln Ala

885

# 890

# 895

cac atc tac cag ctc ttc ctg cgg gat cta cg

#c cag gcg ctc gtg gtg 2736

His Ile Tyr Gln Leu Phe Leu Arg Asp Leu Ar

#g Gln Ala Leu Val Val

900

# 905

# 910

ctg cgt aac cag gag atg gcg ctg tct ggt gc

#g gag ctc ccg ggc aca 2784

Leu Arg Asn Gln Glu Met Ala Leu Ser Gly Al

#a Glu Leu Pro Gly Thr

915

# 920

# 925

gtg gaa tcg gtg gag gag gcc ttg aaa cag ca

#c cgt gac ttt ctc acc 2832

Val Glu Ser Val Glu Glu Ala Leu Lys Gln Hi

#s Arg Asp Phe Leu Thr

930

# 935

# 940

acc atg gag ctg agc cag caa aag atg cag gt

#g gcc gtg cag gct gca 2880

Thr Met Glu Leu Ser Gln Gln Lys Met Gln Va

#l Ala Val Gln Ala Ala

945 9

#50 9

#55 9

#60

gag ggc ctg ctg agg cag ggc aac atc tac gg

#g gag cag gct cag gag 2928

Glu Gly Leu Leu Arg Gln Gly Asn Ile Tyr Gl

#y Glu Gln Ala Gln Glu

965

# 970

# 975

gct gtg acc cgg ctg ctg gag aag aac caa ga

#a aac cag tta cgg gcc 2976

Ala Val Thr Arg Leu Leu Glu Lys Asn Gln Gl

#u Asn Gln Leu Arg Ala

980

# 985

# 990

cag caa tgg atg caa aag cta cat gac caa ct

#t gag ctg cag cac ttc 3024

Gln Gln Trp Met Gln Lys Leu His Asp Gln Le

#u Glu Leu Gln His Phe

995

# 1000

# 1005

ctc cga gac tgc cac gag ctg gat ggc tgg at

#c cat gag aag atg ctg 3072

Leu Arg Asp Cys His Glu Leu Asp Gly Trp Il

#e His Glu Lys Met Leu

1010

# 1015

# 1020

atg gcg cgg gat ggc acg cgg gag gac aac ca

#c aag ctg cat aag aga 3120

Met Ala Arg Asp Gly Thr Arg Glu Asp Asn Hi

#s Lys Leu His Lys Arg

1025 1030

# 1035

# 1040

tgg ctc cgg cac cag gca ttc atg gcc gag ct

#g gct cag aat aag gag 3168

Trp Leu Arg His Gln Ala Phe Met Ala Glu Le

#u Ala Gln Asn Lys Glu

1045

# 1050

# 1055

tgg ctg gag aag atc gag cgg gag ggc cca gc

#a act gat gca gga gaa 3216

Trp Leu Glu Lys Ile Glu Arg Glu Gly Pro Al

#a Thr Asp Ala Gly Glu

1060

# 1065

# 1070

gcc cga act ggc ggc ctc cgt gcg gaa gaa gc

#t ggg cga gat ccg cca 3264

Ala Arg Thr Gly Gly Leu Arg Ala Glu Glu Al

#a Gly Arg Asp Pro Pro

1075

# 1080

# 1085

gtg ctg ggc gga gct gga gag cac cac cca gg

#c cca agg cac ggc agc 3312

Val Leu Gly Gly Ala Gly Glu His His Pro Gl

#y Pro Arg His Gly Ser

1090

# 1095

# 1100

tct ttg agg ccc agc aaa gca gac cag ctg gt

#g cag agc ttt gct gag 3360

Ser Leu Arg Pro Ser Lys Ala Asp Gln Leu Va

#l Gln Ser Phe Ala Glu

1105 1110

# 1115

# 1120

ctg gac aag aag ctc ctt cac atg gag agc ca

#g ctg caa gac gtg gac 3408

Leu Asp Lys Lys Leu Leu His Met Glu Ser Gl

#n Leu Gln Asp Val Asp

1125

# 1130

# 1135

cct gga gga gac ctg gcc act gtc aac agt ca

#g ctc aag aag ctg cag 3456

Pro Gly Gly Asp Leu Ala Thr Val Asn Ser Gl

#n Leu Lys Lys Leu Gln

1140

# 1145

# 1150

tcc atg gag tcg cag gtg gag gag tgg tac cg

#c gag gtg gga gag ctg 3504

Ser Met Glu Ser Gln Val Glu Glu Trp Tyr Ar

#g Glu Val Gly Glu Leu

1155

# 1160

# 1165

cag gcg cag acg gcg gcg ctg ccg ctg gag cc

#g gcg agc aag gag ctg 3552

Gln Ala Gln Thr Ala Ala Leu Pro Leu Glu Pr

#o Ala Ser Lys Glu Leu

1170

# 1175

# 1180

gtg ggt gag cgg cag aac gcg gtg ggc gag cg

#c ctg gtg cgc ctg ctc 3600

Val Gly Glu Arg Gln Asn Ala Val Gly Glu Ar

#g Leu Val Arg Leu Leu

1185 1190

# 1195

# 1200

gag ccg ttg cag gag cgc cgc cgc ttg ctg ct

#g gct tcc aag gag ttg 3648

Glu Pro Leu Gln Glu Arg Arg Arg Leu Leu Le

#u Ala Ser Lys Glu Leu

1205

# 1210

# 1215

cac cag gtg gcg cac gac ctg gac gac gag ct

#g gca tgg gtt cag gag 3696

His Gln Val Ala His Asp Leu Asp Asp Glu Le

#u Ala Trp Val Gln Glu

1220

# 1225

# 1230

cgg ctg cca ctg gcc atg cag aca gag cga gg

#c aac ggt ttg cag gcg 3744

Arg Leu Pro Leu Ala Met Gln Thr Glu Arg Gl

#y Asn Gly Leu Gln Ala

1235

# 1240

# 1245

gtc cag cag cac atc aaa aag aac cag ggc ct

#g cgg cgg gag atc cag 3792

Val Gln Gln His Ile Lys Lys Asn Gln Gly Le

#u Arg Arg Glu Ile Gln

1250

# 1255

# 1260

gcg cat ggg ccg cgc ctg gag gag gtg ctg ga

#g cgc gcg ggc gcg ctg 3840

Ala His Gly Pro Arg Leu Glu Glu Val Leu Gl

#u Arg Ala Gly Ala Leu

1265 1270

# 1275

# 1280

gcg tcg ctg cgc agc ccg gag gca gag gca gt

#g cgc cgg ggc ctg gag 3888

Ala Ser Leu Arg Ser Pro Glu Ala Glu Ala Va

#l Arg Arg Gly Leu Glu

1285

# 1290

# 1295

cag ctg cag agc gcc tgg gcc gga ctg cgg ga

#g gct gcc gag cga cgg 3936

Gln Leu Gln Ser Ala Trp Ala Gly Leu Arg Gl

#u Ala Ala Glu Arg Arg

1300

# 1305

# 1310

cag cag gtg ctg gac gcc gcc ttc cag gtg ga

#g cag tac tac ttc gac 3984

Gln Gln Val Leu Asp Ala Ala Phe Gln Val Gl

#u Gln Tyr Tyr Phe Asp

1315

# 1320

# 1325

gtg gct gag gtg gag gcg tgg ctg ggc gag ca

#g gag ctg ctc atg atg 4032

Val Ala Glu Val Glu Ala Trp Leu Gly Glu Gl

#n Glu Leu Leu Met Met

1330

# 1335

# 1340

agt gag gac aag ggc aag gtg cgc ccg agc tg

#g ggg tgc gga ggg cct 4080

Ser Glu Asp Lys Gly Lys Val Arg Pro Ser Tr

#p Gly Cys Gly Gly Pro

1345 1350

# 1355

# 1360

ggg ggc gct gga gcc ggg ggc cgc cgc tgc cg

#c ctc atc gtg ggc gct 4128

Gly Gly Ala Gly Ala Gly Gly Arg Arg Cys Ar

#g Leu Ile Val Gly Ala

1365

# 1370

# 1375

ttg tgc ccc cag gac gaa cag agc acc ctg ca

#g ctg ctc aag aaa cac 4176

Leu Cys Pro Gln Asp Glu Gln Ser Thr Leu Gl

#n Leu Leu Lys Lys His

1380

# 1385

# 1390

ctg cag ctg gag caa ggc gtg gag aac tac ga

#g gaa agc atc gcg cag 4224

Leu Gln Leu Glu Gln Gly Val Glu Asn Tyr Gl

#u Glu Ser Ile Ala Gln

1395

# 1400

# 1405

ctg tcg cgc cag tgc cgg gcg ctg ctg gag at

#g ggg cac ccg gac agc 4272

Leu Ser Arg Gln Cys Arg Ala Leu Leu Glu Me

#t Gly His Pro Asp Ser

1410

# 1415

# 1420

gag cag atc agc cgg cgg cag tct cag gtg ga

#c cgc ctg tac gtg gcg 4320

Glu Gln Ile Ser Arg Arg Gln Ser Gln Val As

#p Arg Leu Tyr Val Ala

1425 1430

# 1435

# 1440

ctc aag gag ctg ggt gag gag cgc cgg gtg gc

#t ctg gaa cag cag tac 4368

Leu Lys Glu Leu Gly Glu Glu Arg Arg Val Al

#a Leu Glu Gln Gln Tyr

1445

# 1450

# 1455

tgg ctg tac cag ctc agc cgc cag gtg agc ga

#g ctt gag cac tgg att 4416

Trp Leu Tyr Gln Leu Ser Arg Gln Val Ser Gl

#u Leu Glu His Trp Ile

1460

# 1465

# 1470

gcc gag aag gag gtg gtg gct ggc tca ccc ga

#g ctc ggc cag gac ttt 4464

Ala Glu Lys Glu Val Val Ala Gly Ser Pro Gl

#u Leu Gly Gln Asp Phe

1475

# 1480

# 1485

gag cat gtc tcg gtg ctg cag gag aaa ttc tc

#a gag ttt gcc agc gag 4512

Glu His Val Ser Val Leu Gln Glu Lys Phe Se

#r Glu Phe Ala Ser Glu

1490

# 1495

# 1500

aca ggt atg gca ggg cgg gaa cgg ctg gca gc

#t gtg aac cag atg gtg 4560

Thr Gly Met Ala Gly Arg Glu Arg Leu Ala Al

#a Val Asn Gln Met Val

1505 1510

# 1515

# 1520

gat gag ctg atc gag tgt ggc cat aca gca gc

#g gcc acc atg gcc gag 4608

Asp Glu Leu Ile Glu Cys Gly His Thr Ala Al

#a Ala Thr Met Ala Glu

1525

# 1530

# 1535

tgg aag gac gga ctg aac gag gcc tgg gct ga

#g ctg ctg gag ctc atg 4656

Trp Lys Asp Gly Leu Asn Glu Ala Trp Ala Gl

#u Leu Leu Glu Leu Met

1540

# 1545

# 1550

ggc aca cgg gcc cag ctg ctg gcc gcc tct cg

#g gag ctt cat aag ttc 4704

Gly Thr Arg Ala Gln Leu Leu Ala Ala Ser Ar

#g Glu Leu His Lys Phe

1555

# 1560

# 1565

ttc agt gac gcc cga gag ctt cag gga cag at

#t gag gag aag cgg agg 4752

Phe Ser Asp Ala Arg Glu Leu Gln Gly Gln Il

#e Glu Glu Lys Arg Arg

1570

# 1575

# 1580

cgg ctg ccc cgc ctg acc acc ccg cct gag cc

#g aga ccc agt gcc agt 4800

Arg Leu Pro Arg Leu Thr Thr Pro Pro Glu Pr

#o Arg Pro Ser Ala Ser

1585 1590

# 1595

# 1600

tcc atg cag cgg acc ctg aga gcc ttt gag ca

#t gac ctg cag ctc ctc 4848

Ser Met Gln Arg Thr Leu Arg Ala Phe Glu Hi

#s Asp Leu Gln Leu Leu

1605

# 1610

# 1615

gtg tcc cag gta cgg cag ctg cag gag ggg gc

#g gcc cag ctg cgg acg 4896

Val Ser Gln Val Arg Gln Leu Gln Glu Gly Al

#a Ala Gln Leu Arg Thr

1620

# 1625

# 1630

gtg tat gcg ggt gaa cat gcc gag gcc atc gc

#t agc cgg gag cag gag 4944

Val Tyr Ala Gly Glu His Ala Glu Ala Ile Al

#a Ser Arg Glu Gln Glu

1635

# 1640

# 1645

gtg ctg cag ggt tgg aaa gag ctg ctg tca gc

#c tgt gag gat gcc cgc 4992

Val Leu Gln Gly Trp Lys Glu Leu Leu Ser Al

#a Cys Glu Asp Ala Arg

1650

# 1655

# 1660

ctg cat gtc agc tcc aca gcc gac gcc ctg cg

#c ttc cac agc caa gtc 5040

Leu His Val Ser Ser Thr Ala Asp Ala Leu Ar

#g Phe His Ser Gln Val

1665 1670

# 1675

# 1680

cgc gac ctg ctc tcc tgg atg gat ggc atc gc

#c agc cag att ggg gca 5088

Arg Asp Leu Leu Ser Trp Met Asp Gly Ile Al

#a Ser Gln Ile Gly Ala

1685

# 1690

# 1695

gcc gac aag ccc agg gac gtg tca tca gtg ga

#g gtg ctc atg aac tac 5136

Ala Asp Lys Pro Arg Asp Val Ser Ser Val Gl

#u Val Leu Met Asn Tyr

1700

# 1705

# 1710

cac cag ggc ctg aag act gag ctg gag gcg cg

#g gtg cct gag ctg acc 5184

His Gln Gly Leu Lys Thr Glu Leu Glu Ala Ar

#g Val Pro Glu Leu Thr

1715

# 1720

# 1725

acc tgc cag gag ctg ggg cga tct ctg ctg ct

#c aac aaa agt gcc atg 5232

Thr Cys Gln Glu Leu Gly Arg Ser Leu Leu Le

#u Asn Lys Ser Ala Met

1730

# 1735

# 1740

gct gat gag atc cag gca cag ctg gac aag ct

#g gga acc agg aag gag 5280

Ala Asp Glu Ile Gln Ala Gln Leu Asp Lys Le

#u Gly Thr Arg Lys Glu

1745 1750

# 1755

# 1760

gag gtg tcg gaa aag tgg gac cgc cat tgg ga

#g tgg ctg cag cag atg 5328

Glu Val Ser Glu Lys Trp Asp Arg His Trp Gl

#u Trp Leu Gln Gln Met

1765

# 1770

# 1775

ctg gag gtg cac cag ttt gcc cag gag gcg gt

#g gtg gct gat gcc tgg 5376

Leu Glu Val His Gln Phe Ala Gln Glu Ala Va

#l Val Ala Asp Ala Trp

1780

# 1785

# 1790

ctg aca gcc cag gag ccg ctc ctg cag agc cg

#g gag ctg ggc agc agc 5424

Leu Thr Ala Gln Glu Pro Leu Leu Gln Ser Ar

#g Glu Leu Gly Ser Ser

1795

# 1800

# 1805

gtg gat gag gtg gag cag ctt atc cgg cga ca

#t gag gcc ttc cgc aaa 5472

Val Asp Glu Val Glu Gln Leu Ile Arg Arg Hi

#s Glu Ala Phe Arg Lys

1810

# 1815

# 1820

gcg gct gca gcc tgg gaa gag agg ttc agc tc

#t ctg cgg cgc ctg acc 5520

Ala Ala Ala Ala Trp Glu Glu Arg Phe Ser Se

#r Leu Arg Arg Leu Thr

1825 1830

# 1835

# 1840

acg atc gag aaa atc aaa gcg gaa cag agc aa

#g cag ccg cct acc cca 5568

Thr Ile Glu Lys Ile Lys Ala Glu Gln Ser Ly

#s Gln Pro Pro Thr Pro

1845

# 1850

# 1855

ctg ctg ggg cgc aag ttc ttt ggg gac ccc ac

#g gaa ctg gcg gcc aag 5616

Leu Leu Gly Arg Lys Phe Phe Gly Asp Pro Th

#r Glu Leu Ala Ala Lys

1860

# 1865

# 1870

gcg gcg ccc ctg ctg cgg cca ggg ggc tat ga

#a agg ggc ttg gag ccc 5664

Ala Ala Pro Leu Leu Arg Pro Gly Gly Tyr Gl

#u Arg Gly Leu Glu Pro

1875

# 1880

# 1885

ctg gcc cgc cga gcc tcg gac acg ctc tcg gc

#c gag gtg cgg act cgg 5712

Leu Ala Arg Arg Ala Ser Asp Thr Leu Ser Al

#a Glu Val Arg Thr Arg

1890

# 1895

# 1900

gtg ggg tat gtg cgc cag gag ctc aag ccc ga

#g cgc ctc cag ccg cgc 5760

Val Gly Tyr Val Arg Gln Glu Leu Lys Pro Gl

#u Arg Leu Gln Pro Arg

1905 1910

# 1915

# 1920

att gac cgg ctg ccg gag atc ccg ggg agg gt

#g gag ccc gcg gcc ctg 5808

Ile Asp Arg Leu Pro Glu Ile Pro Gly Arg Va

#l Glu Pro Ala Ala Leu

1925

# 1930

# 1935

ccg gcc gca cca gag gac gcg gcg gag acc cc

#c gcg acc ccc gcg gcg 5856

Pro Ala Ala Pro Glu Asp Ala Ala Glu Thr Pr

#o Ala Thr Pro Ala Ala

1940

# 1945

# 1950

gcg gag cag gtg cgg cca cga ccg gag cgc ca

#g gag tca gct gat cgc 5904

Ala Glu Gln Val Arg Pro Arg Pro Glu Arg Gl

#n Glu Ser Ala Asp Arg

1955

# 1960

# 1965

gcg gag gag ctg ccc agg agg cgg cgg cct ga

#g cgg caa gag tca gtc 5952

Ala Glu Glu Leu Pro Arg Arg Arg Arg Pro Gl

#u Arg Gln Glu Ser Val

1970

# 1975

# 1980

gat caa tcc gag gag gct gcg cgg agg cgg cg

#g ccg gag cgg cag gag 6000

Asp Gln Ser Glu Glu Ala Ala Arg Arg Arg Ar

#g Pro Glu Arg Gln Glu

1985 1990

# 1995

# 2000

tca gcg gag cac gag gcg gca cac agc ctt ac

#c ctg ggc cgc tat gag 6048

Ser Ala Glu His Glu Ala Ala His Ser Leu Th

#r Leu Gly Arg Tyr Glu

2005

# 2010

# 2015

cag atg gag cgg cgg cgc gag cgg cgt gag cg

#g cgc ttg gag cgg cag 6096

Gln Met Glu Arg Arg Arg Glu Arg Arg Glu Ar

#g Arg Leu Glu Arg Gln

2020

# 2025

# 2030

gag tcc agc gaa cag gag atg ccc atc aga gg

#a gac ctg gtc aag ggg 6144

Glu Ser Ser Glu Gln Glu Met Pro Ile Arg Gl

#y Asp Leu Val Lys Gly

2035

# 2040

# 2045

aag gcc acc ctg gct gac att gtg gaa cag ct

#g cag gag aaa gag gca 6192

Lys Ala Thr Leu Ala Asp Ile Val Glu Gln Le

#u Gln Glu Lys Glu Ala

2050

# 2055

# 2060

ggc cca ggg ctg cct gct ggg ccg tcg ctg cc

#t cag cca cgc gag ctt 6240

Gly Pro Gly Leu Pro Ala Gly Pro Ser Leu Pr

#o Gln Pro Arg Glu Leu

2065 2070

# 2075

# 2080

ccc cca ggt cgc ctg ccc aac ggg ctt gag ct

#g ccc gag cgg aca cct 6288

Pro Pro Gly Arg Leu Pro Asn Gly Leu Glu Le

#u Pro Glu Arg Thr Pro

2085

# 2090

# 2095

cgg ccg gac cgg ccc cgg gcg cgg gac cgg cc

#c aag ccg cga cgg cgg 6336

Arg Pro Asp Arg Pro Arg Ala Arg Asp Arg Pr

#o Lys Pro Arg Arg Arg

2100

# 2105

# 2110

ccg cgg ccc aga gag ggt ggt gag ggc ggg gg

#a agc cgg cgc tcg cgc 6384

Pro Arg Pro Arg Glu Gly Gly Glu Gly Gly Gl

#y Ser Arg Arg Ser Arg

2115

# 2120

# 2125

tcc gcc ccg gcc cag ggc ggc tcc gcc ccc gc

#g cct ccg cca ccg ccc 6432

Ser Ala Pro Ala Gln Gly Gly Ser Ala Pro Al

#a Pro Pro Pro Pro Pro

2130

# 2135

# 2140

act cac aca gtg cag cac gag ggc ttc cta ct

#g cgc aag cgc gag ctc 6480

Thr His Thr Val Gln His Glu Gly Phe Leu Le

#u Arg Lys Arg Glu Leu

2145 2150

# 2155

# 2160

gac gct aac cgc aag tcg tcc aac cgg tcg tg

#g gtg agc ctg tac tgt 6528

Asp Ala Asn Arg Lys Ser Ser Asn Arg Ser Tr

#p Val Ser Leu Tyr Cys

2165

# 2170

# 2175

gtg ctt agt aag ggg gaa ctg ggc ttc tac aa

#g gac tcc aag ggc ccg 6576

Val Leu Ser Lys Gly Glu Leu Gly Phe Tyr Ly

#s Asp Ser Lys Gly Pro

2180

# 2185

# 2190

gca tcc ggg agc aca cac ggt ggg gaa ccg ct

#g ctc agc ctg cac aag 6624

Ala Ser Gly Ser Thr His Gly Gly Glu Pro Le

#u Leu Ser Leu His Lys

2195

# 2200

# 2205

gcc acc agc gag gtg gct agt gac tac aag aa

#a aag aag cat gtc ttc 6672

Ala Thr Ser Glu Val Ala Ser Asp Tyr Lys Ly

#s Lys Lys His Val Phe

2210

# 2215

# 2220

aag ctc cag acc cag gat ggc agt gag ttt tt

#g ctc cag gca aaa gat 6720

Lys Leu Gln Thr Gln Asp Gly Ser Glu Phe Le

#u Leu Gln Ala Lys Asp

2225 2230

# 2235

# 2240

gag gag gag atg aac ggc tgg ctg gag gct gt

#a gct tcc tcg gtg gcg 6768

Glu Glu Glu Met Asn Gly Trp Leu Glu Ala Va

#l Ala Ser Ser Val Ala

2245

# 2250

# 2255

gaa cac gca gag atc gcc cgc tgg ggc cag ac

#a cta ccc act act tca 6816

Glu His Ala Glu Ile Ala Arg Trp Gly Gln Th

#r Leu Pro Thr Thr Ser

2260

# 2265

# 2270

tcc aca gat gag ggc aac cct aag agg gaa gg

#c gga gat cgc agg gcc 6864

Ser Thr Asp Glu Gly Asn Pro Lys Arg Glu Gl

#y Gly Asp Arg Arg Ala

2275

# 2280

# 2285

agc ggg cgc agg aag tgacttccca cccccaggac ctgacacat

#c tcgtctcccc 6919

Ser Gly Arg Arg Lys

2290

tcttttccgc actgtgggca caaagacact ttttcttccg caggggcggg ag

#cccctagt 6979

tccaacactg aggacgcgtg acatggtggg caccggaaag gaggggactt ct

#cctgcacc 7039

ccaagaagtg gtggggagat tgctgcccct atagccatat ctcggcccct tc

#ccactcac 7099

cacccccacc ccaggtgctg ggggtccctt atttttatgc aataactgag ct

#tgatgggg 7159

gtgggcaggg ggccagttga gccaagcccc cagccccgat ctgcagatcc tg

#ccccaaga 7219

agctggggtg gtgggggcag taattcctgc ccccctctct gccctaggga tg

#ggcacggg 7279

ggcgctggtg aggtcccctg gaccatccag ggtgctaggg ggcagggagg gg

#acaccccc 7339

tccccgcctt tacctcactt ccaatgctgc cttgatctct gtctgggagg gg

#ggagtgaa 7399

ggggccctag ccccctgcac tccgccgcct cagagccatg cggttaattc ct

#gacttagt 7459

ttatttttgc aaaacgtcga tctcctcctc ccccgccccg catccgcgaa gg

#cttttaat 7519

gggaggggcg tcaaagctca aaactgtttt cctctctcct cccccctcca gt

#tgtaaatg 7579

ccacttcatg aggggagggg cgaggggaag cccacccctg catgcttctg gc

#tggagcac 7639

ctccctgggg agtcggggga ttgggttgtg ggcagtcccc atggccgcct gg

#agaagccg 7699

ctggggcccg ggggtgtggg gcggtgtggc gggcgcacac tgtatgtacc ta

#taataaac 7759

cctttggctt tgaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa

#a 7812

<210> SEQ ID NO 2

<211> LENGTH: 2293

<212> TYPE: PRT

<213> ORGANISM: Human

<400> SEQUENCE: 2

Leu Leu Val Ser Phe Tyr His Tyr Phe Ser Ly

#s Met Lys Ala Leu Ala

1 5

# 10

# 15

Val Glu Gly Lys Ala Val Ser Gly Arg Ala Tr

#p Ile His Arg Thr Val

20

# 25

# 30

Gly Xaa Ile Ser Asn Gln Lys Phe Ala Asn Se

#r Leu Ser Gly Val Gln

35

# 40

# 45

Gln Gln Leu Gln Ala Phe Thr Ala Tyr Cys Th

#r Leu Glu Lys Pro Val

50

# 55

# 60

Lys Phe Gln Glu Lys Gly Asn Leu Glu Val Le

#u Leu Phe Ser Ile Gln

65

#70

#75

#80

Ser Lys Leu Arg Ala Cys Asn Arg Arg Leu Ph

#e Val Pro Arg Glu Gly

85

# 90

# 95

Cys Gly Ile Trp Asp Ile Asp Lys Ala Trp Gl

#y Glu Leu Glu Lys Ala

100

# 105

# 110

Glu His Glu Arg Glu Ala Ala Leu Arg Ala Gl

#u Leu Ile Arg Gln Glu

115

# 120

# 125

Lys Leu Glu Leu Leu Ala Gln Arg Phe Asp Hi

#s Lys Val Ala Met Arg

130

# 135

# 140

Glu Ser Trp Leu Asn Glu Asn Gln Arg Leu Va

#l Ser Gln Asp Asn Phe

145 1

#50 1

#55 1

#60

Gly Tyr Glu Leu Pro Ala Val Glu Ala Ala Me

#t Lys Lys His Glu Ala

165

# 170

# 175

Ile Glu Ala Asp Ile Ala Ala Tyr Glu Glu Ar

#g Val Gln Gly Val Ala

180

# 185

# 190

Glu Leu Ala Gln Ala Leu Ala Ala Glu Gly Ty

#r Tyr Asp Ile Arg Arg

195

# 200

# 205

Val Ala Ala Gln Arg Asp Ser Val Leu Arg Gl

#n Trp Ala Leu Leu Thr

210

# 215

# 220

Gly Leu Val Gly Ala Arg Arg Thr Arg Leu Gl

#u Gln Asn Leu Ala Leu

225 2

#30 2

#35 2

#40

Gln Lys Val Phe Gln Glu Met Val Tyr Met Va

#l Asp Trp Met Glu Glu

245

# 250

# 255

Met Gln Ala Gln Leu Leu Ser Arg Glu Cys Gl

#y Gln His Leu Val Glu

260

# 265

# 270

Ala Asp Asp Leu Leu Gln Lys His Gly Leu Le

#u Glu Gly Asp Ile Ala

275

# 280

# 285

Ala Gln Ser Glu Arg Val Glu Ala Leu Asn Al

#a Ala Ala Leu Arg Phe

290

# 295

# 300

Ser Gln Pro Cys Asp Pro Gln Val Ile Cys As

#n Arg Val Asn His Val

305 3

#10 3

#15 3

#20

His Gly Cys Leu Ala Glu Leu Gln Glu Gln Al

#a Ala Arg Arg Arg Ala

325

# 330

# 335

Glu Leu Glu Ala Xaa Arg Ser Leu Trp Ala Le

#u Leu Gln Glu Leu Glu

340

# 345

# 350

Glu Ala Glu Ser Trp Ala Arg Asp Lys Glu Ar

#g Leu Leu Glu Ala Ala

355

# 360

# 365

Gly Gly Gly Gly Ala Ala Gly Ala Ala Gly Al

#a Ala Gly Thr Ala Gly

370

# 375

# 380

Gly Ala His Asp Leu Ser Ser Thr Ala Arg Le

#u Leu Ala Gln His Lys

385 3

#90 3

#95 4

#00

Ile Leu Gln Gly Glu Leu Gly Gly Arg Arg Al

#a Ser Leu Gln Gln Ala

405

# 410

# 415

Leu Arg Cys Gly Glu Glu Leu Val Ala Ala Gl

#y Gly Ala Val Gly Pro

420

# 425

# 430

Gly Ala Asp Thr Val His Leu Val Gly Leu Al

#a Glu Arg Ala Ala Ser

435

# 440

# 445

Ala Arg Arg Arg Trp Gln Arg Leu Glu Glu Al

#a Ala Ala Arg Arg Glu

450

# 455

# 460

Arg Arg Leu Gln Glu Ala Arg Ala Leu His Gl

#n Phe Gly Ala Asp Leu

465 4

#70 4

#75 4

#80

Asp Gly Leu Leu Asp Trp Leu Arg Asp Ala Ty

#r Arg Leu Ala Ala Ala

485

# 490

# 495

Gly Asp Phe Gly His Asp Glu Ala Ser Ser Ar

#g Arg Leu Ala Arg Gln

500

# 505

# 510

His Arg Ala Leu Thr Gly Glu Val Glu Ala Hi

#s Arg Gly Pro Val Ser

515

# 520

# 525

Gly Leu Arg Arg Gln Leu Ala Thr Leu Gly Gl

#y Ala Ser Gly Ala Gly

530

# 535

# 540

Pro Leu Val Val Ala Leu Gln Val Arg Val Va

#l Glu Ala Glu Gln Leu

545 5

#50 5

#55 5

#60

Phe Ala Glu Val Thr Glu Val Ala Ala Leu Ar

#g Arg Gln Trp Leu Arg

565

# 570

# 575

Asp Ala Leu Ala Val Tyr Arg Met Phe Gly Gl

#u Val His Ala Cys Glu

580

# 585

# 590

Leu Trp Ile Gly Glu Lys Glu Gln Trp Leu Le

#u Ser Met Arg Val Pro

595

# 600

# 605

Asp Ser Leu Asp Asp Val Glu Val Val Gln Hi

#s Arg Phe Glu Ser Leu

610

# 615

# 620

Asp Gln Glu Met Asn Ser Leu Met Gly Arg Va

#l Leu Asp Val Asn His

625 6

#30 6

#35 6

#40

Thr Val Gln Glu Leu Val Glu Gly Gly His Pr

#o Ser Ser Asp Glu Val

645

# 650

# 655

Arg Ser Cys Gln Asp His Leu Asn Ser Arg Tr

#p Asn Arg Ile Val Glu

660

# 665

# 670

Leu Val Glu Gln Arg Lys Glu Glu Met Ser Al

#a Val Leu Leu Val Glu

675

# 680

# 685

Asn His Val Leu Glu Val Ala Glu Val Arg Al

#a Gln Val Arg Glu Lys

690

# 695

# 700

Arg Arg Ala Val Glu Ser Ala Pro Arg Ala Gl

#y Gly Ala Leu Gln Trp

705 7

#10 7

#15 7

#20

Arg Leu Ser Gly Leu Glu Ala Ala Leu Gln Al

#a Leu Glu Pro Arg Gln

725

# 730

# 735

Ala Ala Leu Leu Glu Glu Ala Ala Leu Leu Al

#a Glu Arg Phe Pro Ala

740

# 745

# 750

Gln Ala Ala Xaa Leu His Gln Gly Ala Glu Gl

#u Leu Gly Ala Glu Trp

755

# 760

# 765

Gly Ala Leu Ala Ser Ala Ala Gln Ala Cys Gl

#y Glu Ala Val Ala Ala

770

# 775

# 780

Ala Gly Arg Leu Gln Arg Phe Leu His Asp Le

#u Asp Ala Phe Leu Asp

785 7

#90 7

#95 8

#00

Trp Leu Val Arg Ala Gln Glu Ala Ala Gly Gl

#y Ser Glu Gly Pro Leu

805

# 810

# 815

Pro Asn Ser Leu Glu Glu Ala Asp Ala Leu Le

#u Ala Arg His Ala Ala

820

# 825

# 830

Leu Lys Glu Glu Val Asp Gln Arg Glu Glu As

#p Tyr Ala Arg Ile Val

835

# 840

# 845

Ala Ala Ser Glu Ala Leu Leu Ala Ala Asp Gl

#y Ala Glu Leu Gly Pro

850

# 855

# 860

Gly Leu Ala Leu Asp Glu Trp Leu Pro His Le

#u Glu Leu Gly Trp His

865 8

#70 8

#75 8

#80

Lys Leu Leu Gly Leu Trp Lys Ala Arg Arg Ly

#s Ala Leu Val Gln Ala

885

# 890

# 895

His Ile Tyr Gln Leu Phe Leu Arg Asp Leu Ar

#g Gln Ala Leu Val Val

900

# 905

# 910

Leu Arg Asn Gln Glu Met Ala Leu Ser Gly Al

#a Glu Leu Pro Gly Thr

915

# 920

# 925

Val Glu Ser Val Glu Glu Ala Leu Lys Gln Hi

#s Arg Asp Phe Leu Thr

930

# 935

# 940

Thr Met Glu Leu Ser Gln Gln Lys Met Gln Va

#l Ala Val Gln Ala Ala

945 9

#50 9

#55 9

#60

Glu Gly Leu Leu Arg Gln Gly Asn Ile Tyr Gl

#y Glu Gln Ala Gln Glu

965

# 970

# 975

Ala Val Thr Arg Leu Leu Glu Lys Asn Gln Gl

#u Asn Gln Leu Arg Ala

980

# 985

# 990

Gln Gln Trp Met Gln Lys Leu His Asp Gln Le

#u Glu Leu Gln His Phe

995

# 1000

# 1005

Leu Arg Asp Cys His Glu Leu Asp Gly Trp Il

#e His Glu Lys Met Leu

1010

# 1015

# 1020

Met Ala Arg Asp Gly Thr Arg Glu Asp Asn Hi

#s Lys Leu His Lys Arg

1025 1030

# 1035

# 1040

Trp Leu Arg His Gln Ala Phe Met Ala Glu Le

#u Ala Gln Asn Lys Glu

1045

# 1050

# 1055

Trp Leu Glu Lys Ile Glu Arg Glu Gly Pro Al

#a Thr Asp Ala Gly Glu

1060

# 1065

# 1070

Ala Arg Thr Gly Gly Leu Arg Ala Glu Glu Al

#a Gly Arg Asp Pro Pro

1075

# 1080

# 1085

Val Leu Gly Gly Ala Gly Glu His His Pro Gl

#y Pro Arg His Gly Ser

1090

# 1095

# 1100

Ser Leu Arg Pro Ser Lys Ala Asp Gln Leu Va

#l Gln Ser Phe Ala Glu

1105 1110

# 1115

# 1120

Leu Asp Lys Lys Leu Leu His Met Glu Ser Gl

#n Leu Gln Asp Val Asp

1125

# 1130

# 1135

Pro Gly Gly Asp Leu Ala Thr Val Asn Ser Gl

#n Leu Lys Lys Leu Gln

1140

# 1145

# 1150

Ser Met Glu Ser Gln Val Glu Glu Trp Tyr Ar

#g Glu Val Gly Glu Leu

1155

# 1160

# 1165

Gln Ala Gln Thr Ala Ala Leu Pro Leu Glu Pr

#o Ala Ser Lys Glu Leu

1170

# 1175

# 1180

Val Gly Glu Arg Gln Asn Ala Val Gly Glu Ar

#g Leu Val Arg Leu Leu

1185 1190

# 1195

# 1200

Glu Pro Leu Gln Glu Arg Arg Arg Leu Leu Le

#u Ala Ser Lys Glu Leu

1205

# 1210

# 1215

His Gln Val Ala His Asp Leu Asp Asp Glu Le

#u Ala Trp Val Gln Glu

1220

# 1225

# 1230

Arg Leu Pro Leu Ala Met Gln Thr Glu Arg Gl

#y Asn Gly Leu Gln Ala

1235

# 1240

# 1245

Val Gln Gln His Ile Lys Lys Asn Gln Gly Le

#u Arg Arg Glu Ile Gln

1250

# 1255

# 1260

Ala His Gly Pro Arg Leu Glu Glu Val Leu Gl

#u Arg Ala Gly Ala Leu

1265 1270

# 1275

# 1280

Ala Ser Leu Arg Ser Pro Glu Ala Glu Ala Va

#l Arg Arg Gly Leu Glu

1285

# 1290

# 1295

Gln Leu Gln Ser Ala Trp Ala Gly Leu Arg Gl

#u Ala Ala Glu Arg Arg

1300

# 1305

# 1310

Gln Gln Val Leu Asp Ala Ala Phe Gln Val Gl

#u Gln Tyr Tyr Phe Asp

1315

# 1320

# 1325

Val Ala Glu Val Glu Ala Trp Leu Gly Glu Gl

#n Glu Leu Leu Met Met

1330

# 1335

# 1340

Ser Glu Asp Lys Gly Lys Val Arg Pro Ser Tr

#p Gly Cys Gly Gly Pro

1345 1350

# 1355

# 1360

Gly Gly Ala Gly Ala Gly Gly Arg Arg Cys Ar

#g Leu Ile Val Gly Ala

1365

# 1370

# 1375

Leu Cys Pro Gln Asp Glu Gln Ser Thr Leu Gl

#n Leu Leu Lys Lys His

1380

# 1385

# 1390

Leu Gln Leu Glu Gln Gly Val Glu Asn Tyr Gl

#u Glu Ser Ile Ala Gln

1395

# 1400

# 1405

Leu Ser Arg Gln Cys Arg Ala Leu Leu Glu Me

#t Gly His Pro Asp Ser

1410

# 1415

# 1420

Glu Gln Ile Ser Arg Arg Gln Ser Gln Val As

#p Arg Leu Tyr Val Ala

1425 1430

# 1435

# 1440

Leu Lys Glu Leu Gly Glu Glu Arg Arg Val Al

#a Leu Glu Gln Gln Tyr

1445

# 1450

# 1455

Trp Leu Tyr Gln Leu Ser Arg Gln Val Ser Gl

#u Leu Glu His Trp Ile

1460

# 1465

# 1470

Ala Glu Lys Glu Val Val Ala Gly Ser Pro Gl

#u Leu Gly Gln Asp Phe

1475

# 1480

# 1485

Glu His Val Ser Val Leu Gln Glu Lys Phe Se

#r Glu Phe Ala Ser Glu

1490

# 1495

# 1500

Thr Gly Met Ala Gly Arg Glu Arg Leu Ala Al

#a Val Asn Gln Met Val

1505 1510

# 1515

# 1520

Asp Glu Leu Ile Glu Cys Gly His Thr Ala Al

#a Ala Thr Met Ala Glu

1525

# 1530

# 1535

Trp Lys Asp Gly Leu Asn Glu Ala Trp Ala Gl

#u Leu Leu Glu Leu Met

1540

# 1545

# 1550

Gly Thr Arg Ala Gln Leu Leu Ala Ala Ser Ar

#g Glu Leu His Lys Phe

1555

# 1560

# 1565

Phe Ser Asp Ala Arg Glu Leu Gln Gly Gln Il

#e Glu Glu Lys Arg Arg

1570

# 1575

# 1580

Arg Leu Pro Arg Leu Thr Thr Pro Pro Glu Pr

#o Arg Pro Ser Ala Ser

1585 1590

# 1595

# 1600

Ser Met Gln Arg Thr Leu Arg Ala Phe Glu Hi

#s Asp Leu Gln Leu Leu

1605

# 1610

# 1615

Val Ser Gln Val Arg Gln Leu Gln Glu Gly Al

#a Ala Gln Leu Arg Thr

1620

# 1625

# 1630

Val Tyr Ala Gly Glu His Ala Glu Ala Ile Al

#a Ser Arg Glu Gln Glu

1635

# 1640

# 1645

Val Leu Gln Gly Trp Lys Glu Leu Leu Ser Al

#a Cys Glu Asp Ala Arg

1650

# 1655

# 1660

Leu His Val Ser Ser Thr Ala Asp Ala Leu Ar

#g Phe His Ser Gln Val

1665 1670

# 1675

# 1680

Arg Asp Leu Leu Ser Trp Met Asp Gly Ile Al

#a Ser Gln Ile Gly Ala

1685

# 1690

# 1695

Ala Asp Lys Pro Arg Asp Val Ser Ser Val Gl

#u Val Leu Met Asn Tyr

1700

# 1705

# 1710

His Gln Gly Leu Lys Thr Glu Leu Glu Ala Ar

#g Val Pro Glu Leu Thr

1715

# 1720

# 1725

Thr Cys Gln Glu Leu Gly Arg Ser Leu Leu Le

#u Asn Lys Ser Ala Met

1730

# 1735

# 1740

Ala Asp Glu Ile Gln Ala Gln Leu Asp Lys Le

#u Gly Thr Arg Lys Glu

1745 1750

# 1755

# 1760

Glu Val Ser Glu Lys Trp Asp Arg His Trp Gl

#u Trp Leu Gln Gln Met

1765

# 1770

# 1775

Leu Glu Val His Gln Phe Ala Gln Glu Ala Va

#l Val Ala Asp Ala Trp

1780

# 1785

# 1790

Leu Thr Ala Gln Glu Pro Leu Leu Gln Ser Ar

#g Glu Leu Gly Ser Ser

1795

# 1800

# 1805

Val Asp Glu Val Glu Gln Leu Ile Arg Arg Hi

#s Glu Ala Phe Arg Lys

1810

# 1815

# 1820

Ala Ala Ala Ala Trp Glu Glu Arg Phe Ser Se

#r Leu Arg Arg Leu Thr

1825 1830

# 1835

# 1840

Thr Ile Glu Lys Ile Lys Ala Glu Gln Ser Ly

#s Gln Pro Pro Thr Pro

1845

# 1850

# 1855

Leu Leu Gly Arg Lys Phe Phe Gly Asp Pro Th

#r Glu Leu Ala Ala Lys

1860

# 1865

# 1870

Ala Ala Pro Leu Leu Arg Pro Gly Gly Tyr Gl

#u Arg Gly Leu Glu Pro

1875

# 1880

# 1885

Leu Ala Arg Arg Ala Ser Asp Thr Leu Ser Al

#a Glu Val Arg Thr Arg

1890

# 1895

# 1900

Val Gly Tyr Val Arg Gln Glu Leu Lys Pro Gl

#u Arg Leu Gln Pro Arg

1905 1910

# 1915

# 1920

Ile Asp Arg Leu Pro Glu Ile Pro Gly Arg Va

#l Glu Pro Ala Ala Leu

1925

# 1930

# 1935

Pro Ala Ala Pro Glu Asp Ala Ala Glu Thr Pr

#o Ala Thr Pro Ala Ala

1940

# 1945

# 1950

Ala Glu Gln Val Arg Pro Arg Pro Glu Arg Gl

#n Glu Ser Ala Asp Arg

1955

# 1960

# 1965

Ala Glu Glu Leu Pro Arg Arg Arg Arg Pro Gl

#u Arg Gln Glu Ser Val

1970

# 1975

# 1980

Asp Gln Ser Glu Glu Ala Ala Arg Arg Arg Ar

#g Pro Glu Arg Gln Glu

1985 1990

# 1995

# 2000

Ser Ala Glu His Glu Ala Ala His Ser Leu Th

#r Leu Gly Arg Tyr Glu

2005

# 2010

# 2015

Gln Met Glu Arg Arg Arg Glu Arg Arg Glu Ar

#g Arg Leu Glu Arg Gln

2020

# 2025

# 2030

Glu Ser Ser Glu Gln Glu Met Pro Ile Arg Gl

#y Asp Leu Val Lys Gly

2035

# 2040

# 2045

Lys Ala Thr Leu Ala Asp Ile Val Glu Gln Le

#u Gln Glu Lys Glu Ala

2050

# 2055

# 2060

Gly Pro Gly Leu Pro Ala Gly Pro Ser Leu Pr

#o Gln Pro Arg Glu Leu

2065 2070

# 2075

# 2080

Pro Pro Gly Arg Leu Pro Asn Gly Leu Glu Le

#u Pro Glu Arg Thr Pro

2085

# 2090

# 2095

Arg Pro Asp Arg Pro Arg Ala Arg Asp Arg Pr

#o Lys Pro Arg Arg Arg

2100

# 2105

# 2110

Pro Arg Pro Arg Glu Gly Gly Glu Gly Gly Gl

#y Ser Arg Arg Ser Arg

2115

# 2120

# 2125

Ser Ala Pro Ala Gln Gly Gly Ser Ala Pro Al

#a Pro Pro Pro Pro Pro

2130

# 2135

# 2140

Thr His Thr Val Gln His Glu Gly Phe Leu Le

#u Arg Lys Arg Glu Leu

2145 2150

# 2155

# 2160

Asp Ala Asn Arg Lys Ser Ser Asn Arg Ser Tr

#p Val Ser Leu Tyr Cys

2165

# 2170

# 2175

Val Leu Ser Lys Gly Glu Leu Gly Phe Tyr Ly

#s Asp Ser Lys Gly Pro

2180

# 2185

# 2190

Ala Ser Gly Ser Thr His Gly Gly Glu Pro Le

#u Leu Ser Leu His Lys

2195

# 2200

# 2205

Ala Thr Ser Glu Val Ala Ser Asp Tyr Lys Ly

#s Lys Lys His Val Phe

2210

# 2215

# 2220

Lys Leu Gln Thr Gln Asp Gly Ser Glu Phe Le

#u Leu Gln Ala Lys Asp

2225 2230

# 2235

# 2240

Glu Glu Glu Met Asn Gly Trp Leu Glu Ala Va

#l Ala Ser Ser Val Ala

2245

# 2250

# 2255

Glu His Ala Glu Ile Ala Arg Trp Gly Gln Th

#r Leu Pro Thr Thr Ser

2260

# 2265

# 2270

Ser Thr Asp Glu Gly Asn Pro Lys Arg Glu Gl

#y Gly Asp Arg Arg Ala

2275

# 2280

# 2285

Ser Gly Arg Arg Lys

2290

<210> SEQ ID NO 3

<211> LENGTH: 5

<212> TYPE: PRT

<213> ORGANISM: Human

<400> SEQUENCE: 3

Glu Arg Asn Glu Ser

1 5

<210> SEQ ID NO 4

<211> LENGTH: 29

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: 5′ primer sequence

<400> SEQUENCE: 4

cctcagctgg ccggacgagg gcacaccgg

#

# 29

<210> SEQ ID NO 5

<211> LENGTH: 29

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: 3′ primer sequence

<400> SEQUENCE: 5

ccggtgtgcc ctcgtccggc cagctgagg

#

# 29

<210> SEQ ID NO 6

<211> LENGTH: 27

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: 5′ primer sequence

<400> SEQUENCE: 6

cgtgcactgc tcggccggtg cggggag

#

# 27

<210> SEQ ID NO 7

<211> LENGTH: 26

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: 3′ primer sequence

<400> SEQUENCE: 7

ctccccgcac cggccgagca gtgcac

#

# 26

<210> SEQ ID NO 8

<211> LENGTH: 21

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic peptide for Ant

#ibody preparation

<400> SEQUENCE: 8

Cys Glu Glu Leu Pro Arg Arg Arg Arg Pro Gl

#u Arg Gln Glu Ser Val

1 5

# 10

# 15

Asp Gln Ser Glu Glu

20

Number	Name	Date
3791932	Wilhelmus et al.	Feb 1974
3817837	Rubestein et al.	Jun 1974
3839153	Wilhelmus et al.	Oct 1974
3850578	McConnell	Nov 1974
3850752	Schuurs et al.	Nov 1974
3853987	Dreyer	Dec 1974
3867517	Ling	Feb 1975
3879262	Schuurs et al.	Apr 1975
3901654	Gross	Aug 1975
3925074	Wyhof	Dec 1975
3984533	Uzgiris	Oct 1976
3996345	Ullman et al.	Dec 1976
4034074	Miles	Jul 1977
4098876	Piassio et al.	Jul 1978
5512447	Baekkeskov et al.	Apr 1996

βIV-spectrin-polypeptides and nucleic acids encoding same

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

US Classifications

Field of Search

US

International Classifications

Abstract

Description

Claims

Parent Case Info

STATEMENT OF GOVERNMENT SUPPORT

US Referenced Citations (15)

Non-Patent Literature Citations (51)

Provisional Applications (1)

Entry
Solimena, “Vesicular Autoantigens of Type 1 Diabetes”,Diabetes , Metab. Rev. 14:227-240 (1998).
Ferro-Novick et al., “Vesicle fusion from yeast to man”, Nature 370:191-193 (1994).
Martin, T. F., “The Molecular Machinery for Fast and Slow Neurosecretion”, Curr. Opin., Neurobiol. 4:626-632 (1994).
Calakos, N. et al., “Synaptic Vesicle Biogenesis, Docking, and Fusion: A Molecular Description”, Physiol. Rev, 76:1-29 (1996).
Greengard, F. et al., “Synaptic Vesicle Phosphoproteins and Regulation of Synaptic Function”, Science 259:780-785 (1993).
Sorenson, R. L. et al., “Effect of Tyrosine Kinase Inhibitors on Islets of Langerhans: Evidence for Tyrosine Kinases in the Regulation of Insulin Secretion”, Endocrinal.. 134:1975-1978 (1994).
Hay, J. C. et al., “Resolution of Regulated Secretion into Sequential MgATP-dependent Calcium-dependent Stages Mediated by Distinct Cytosolic Proteins”, J. Cell. Biol. 119:139-151 (1992).
Austin, C. D. et al., “Formation of Nascent Secretory Vesicles from the trans-Golgi Network of Endocrine Cells is Inhibited by Tyrosine Kinase and Phosphatase Inhibitors,”, J. Cell. Biol. 135:1471-1483 (1996).
Cataldi, M. et al., “Protein-tyrosine Kinases Activate While Protien-tyrosine Phosphatses Inhibit L-type Calcium Channel Activity in Pituitary GH2 Cells”, Biol. Chem. 271:9441-9446 (1996).
Pang, D. T. et al., “Protein tyrosine phosphorylation in synaptic vesicles”, Proc. Natl. Acad. Sci. USA 85:762-766 (1988).
Stenius, K. et al., “Structure of Synaptogyrin (p29) Defines Novel Synaptic Vesicle Protein”, J. Cell. Biol. 131:1801-1809 (1995.
Parsons, S. J. et al., “p60c-src Activity Detected in the Chromaffin Granule Membrane”, Biochem. Biophys. Res. Comm. 134:736-742 (1986).
Grandiori, C. et al., “p60c-src Is Complexed with a Cellular Protein in Subcellular Compartments Involved in Exocytosis”, J. Cell. Biol. 107:2125-2135 (1988).
Burgoyne, R. D. et al., “Exocytosis in adrenal chromaffin cells”, J. Anat. 183:309-314 (1993).
Sarafian, T. et al., “The Participation of Annexin II (Calpactin I) in Calcium-evoked Exocytosis Requires Protein Kinase C”, J. Cell Biol. 114:1135-1147 (1991).
Hubaishy, I. et al., “Modulation of Annexin II Tetramer by Tyrosine Phosphorylation”, Biochemistry 34:14527-14534 (1995).
Ferrer-Montiel, A. V. et al., “Tyrosine Phosphorylation Modulates the Activity of Clostridial Neurotoxins”, J. Biol. Chem. 271:18322-18325 (1996).
Solimena, M. et al., “ICA 512, an autoantigen of type 1 diabetes, is an intrinsic membrane protein of neurosecretory granules”, EMBO J. 15:2102-2114 (1996).
Rabin, D. U. et al., “Cloning and Expression of IDDM-Specific Human Autoantigens”, Diabetes 41:183-186 (1992).
Rabin, D. U. et al., “Islet Cell Antigen 512 Is a Diabetes-Specific Islet Autoantigen Related to Protein Tyrosine Phosphatases”, J. Immunol. 152:3183-3188 (1994).
Lan, M. S. et al.., “Molecular Cloning and Identification of a Receptor-Type Protein Tyrosine Phosphatase, 1A-2, from Human Insulinoma”, DNA Cell Biol. 13:505-514 (1994).
Strueli, M. et al., “Expression of the receptor-linked protein tyrosine phosphatase LAR: proteolytic cleavage and shedding of the Cam-like extracellular region”, EMBO J, 11:897-907 (1992).
Serra-Pages, C. et al., “Mutational Analysis of Proprotein Processing, Subunit Association, and Shedding of the LAR Transmembrane Protein Tyrosine Phosphatase”, J. Biol. Chem. 269:23632-23641 (1994).
Brady-Kalnay, S. M. et al., “Identification of the Homophilic Binding Site of the Receptor Protein Tyrosine Phosphatase PTPμ”, J. Biol. Chem. 269:284722-28477 (1994).
Pulido, R. et al., “The LAR/PTPδ/PTPσ subfamily of transmembrane protien-tyrosine-phosphatases: Multiple human LAR, PTPδ, and PTP σ isoforms are expressed in a tissue-specific manner and associate with LAR-interacting protein LIP.1”, Proc. Natl. Acad. Sci. USA 92:11686-11690 (1995).
Hermel et al., “Post-translational modifications of ICA512, a receptor tyrosine phosphatase-like protein of secretory granules”, Eur. J. Neurosci. 11:20690 (1999).
Brady-Kulnay, S. M. et al., “Protein tyrosine phosphates as adhesion receptors”, Curr. Opin. Cell Biol. 7:650-657 (1995).
Streuli, M. “Protein tyrosine phosphatases in signaling”, Curr. Opin. Cell Biol. 8:182-188 (1996).
Passini, N. et al., “The 37/40-kilodalton autoantigen in insulin-dependent diabetes mellitus is the putative tyrosine phosphatase IA-2”, Proc. Natl. Acad. Sci. USA 92:9412-9416 (1995).
Lu, J. et al., “Isolation, Sequence and Expression of A Novel Mouse Brain cDNA, mIA-2, And Its Relatedness To Members of the Protein Tyrosine Phosphatase Family”, Biochem. Biophys. Res. Comm. 204:930-936 (1994).
Bult, A. et al., “STEP61: A Member of a Family of Brain-Enriched PTP's Is Localized to the Endoplasmic Reticulum”, Neuroscience 16:7821-7831 (1996).
Wasmeier, C. et al., “Molecular Clonong of Phogrin, a Protein-tyrosine Phosphatase Homologue Localized to Insulin Secretory Granule Membranes”, J. Biol. Chem. 271:18161-18170 (1996).
Pietropaolo, M. et al., “Protein Tyrosine Phosphatase-Like Proteins: Link with IDDM”, Diabetes Care 20:208-214 (1997).
Hatfield, E. C. , “Cross reactivity between IA-2 and phogrin/IA-2β in binding of autoantibodies in IDDM”, Diabetologia 40:1327-1333 (1997).
Magistrelli, G. et al., “Expression of PTP35, The Murine Homologue Of The Protein Tyrosine Phosphatase-Related Sequence IA-2, Is Regulated During Cell Growth And Stimulated by Mitogens in 3T3 Fibroblasts”, Biochem. Biophys. Res. Chem. 217:581-588 (1996).
Debant, Q. et al., “The multidomain protein Trio binds the LAR transmembrane tyrosine phosphatase, contains a protein kinase domain, and has separate rac-specific and rho-specific guanine nucleotide exchange factor domains”, Proc. Natl. Acad. Sci. USA 93:5466-5471 (1996).
Haneji, N. et al., “Identification of α-Fodrin as a Candidate Autoantigen in Primary Sjogren's Syndrome”, Science 276:604-607 (1997).
Yanagi, et al., “Anti-120-kDA α-fodrin immune response with Th1-cytokine profile in the NOD mouse model of Sjogren's syndrome”, Eur. J. Immunol. 28:3336-3345 (1998).
Fields, D. et al., “A novel genetic system to detect protein-protein interactions”, Nature 340:245-246(1989).
Vojtec et al., “Mammalian Ras Interacts Directly with the Serine/Threonine Kinase Raf”, Cell, 74:205-214 (1993).

&#x03B2;IV-spectrin-polypeptides and nucleic acids encoding same

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

US Classifications

Field of Search

US

International Classifications

Abstract

Description

Claims

Parent Case Info

STATEMENT OF GOVERNMENT SUPPORT

US Referenced Citations (15)

Non-Patent Literature Citations (51)

Provisional Applications (1)

βIV-spectrin-polypeptides and nucleic acids encoding same